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7Foreword
The European Monitoring Centre for Drugs and Drug Addiction has great pleasure in 
presenting its eleventh General report of activities to the European Parliament, the Council 
of the European Union, the European Commission and the Member States, following its 
adoption by the Management Board in July 2006.
The report provides a retrospective account of the EMCDDA’s activities and 
accomplishments in 2005, mid-way through its fourth three-year programme (2004–
2006). For the first time, it also includes the Authorising officer’s report and declaration 
of assurance.
One of the most significant events during the year was the nomination of a new Director 
for the Centre. In May 2005, our Management Board elected Wolfgang Götz as 
Director. He has been working at the EMCDDA for many years in various responsible 
roles, first as Head of the Information Department and latterly as Coordinator of the 
Reitox network. On his appointment, he declared that his overriding objective was to 
ensure that the Centre served ever more effectively Member States’ great and growing 
need for comprehensive and reliable information in the drugs field. I am delighted with 
the smooth transition to his leadership and I wish him every success in his work.
In 2005, our day-to-day business of drugs monitoring and analysis concentrated 
on the priorities set out in the triennial work programme. High on our agenda was 
continued assistance to the newer members of the European Union and we invested in 
capacity building and in training activities to support their data collection and analysis 
endeavours. To strengthen the Reitox network as a whole, we further implemented the 
agreed operating system with revised and rationalised reporting tools. 
We continued to provide support to the EU institutions in their various activities in the 
drugs field. We contributed to the European Commission’s work on the new Action 
plan on drugs (2005–2008) helping to draft the action plan itself and answering 
questions on the technical feasibility and scientific relevance of the indicators and tools 
mentioned therein. We assisted in elaborating the first roadmap for its evaluation and 
are contributing to annual review and impact assessment activities. The EMCDDA plays 
an important role in the implementation of the Council Decision on the information 
exchange, risk assessment and control of new psychoactive substances, adopted in May 
2005, and we prioritised the tasks set out for us there in order to ensure a smooth shift 
from the Joint action to the new mechanism.
We enjoyed closer relations with the European Parliament through its Committee on 
Citizens’ Rights Freedoms, Justice and Home Affairs with a successful presentation 
and launch of our Annual report on the state of the drugs problem in Europe. We also 
consolidated work initiated in 2004 in bringing representatives from national parliaments 
to Brussels for the launch and engaging in dialogue with them. We are pleased with the 
continued improvement of the contents and analysis that goes into our report. And also 
the progress made in improving our scientific credibility by making visible the data sets 
that underpin our work in the statistical bulletin. As we become more confident of the 
comparability of our data, we are able to give Member States a better picture of where 
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they stand in terms of drugs problems and this year we introduced country data profiles 
which enable them to see at a glance where they fit into the European situation.
At the close of this year, I would like to offer my heartfelt thanks to the colleagues on 
the Management Board and in the Bureau and staff of the Centre, Reitox national focal 
points and Scientific Committee for their constant support and dedication. I really do 
feel that the Centre has entered a new era with Mr Götz and look forward to seeing the 
results of the new impetus provided through his leadership.
Marcel Reimen 
Chairman of the EMCDDA Management Board
Introduction
I took up my responsibilities on 1 May 2005 and set about ensuring continuity in meeting 
the objectives set out in the ongoing work programme. At the same time, I focused on 
setting some clear strategic priorities for the future direction of the EMCDDA that assure 
the increased quality of its work and more efficient use of resources. The Centre has 
achieved a great deal over the last 10 years, establishing the all-important networks, 
mechanisms and tools to gather sound and comparable drug data. We now need to build 
on these foundations and provide the evidence necessary for informed decision-making 
through sound information.
It is my aim to make the EMCDDA the recognised centre of excellence in European drug 
information and to develop it towards being one of the best managed EU agencies. In my 
first few months as Director I concentrated on three priority areas:
• improving the scientific quality of the Centre’s work and outputs and enhancing its 
credibility;
• providing leadership and applying good management practice;
• building and improving partnerships.
In order to improve the scientific quality of the Centre’s work, I found it necessary 
to review the organisational structure. The four scientific departments and the work 
processes in place did not facilitate thematic cross-departmental cooperation. After an 
internal consultation process among staff on possible alternative set-ups, I reorganised this 
area into two operational scientific programmes, and I also introduced a new scientific 
support programme. The new scientific support programme is responsible for managing 
EMCDDA relations with European and national research partners and the EMCDDA 
Scientific Committee; coordinating the EMCDDA’s presence at scientific conferences and 
the publication of articles in scientific journals; and providing proactive documentary 
support to the abovementioned operational programmes. 
Managing our enlarged data set in an efficient way is crucial to freeing up the time of 
our scientific staff for in-depth, high-quality analysis. It is with this in mind that I turned my 
attention to the development of our information storage and retrieval system – a priority 
project in our 2004–2006 work programme. This project had fallen behind schedule and 
I allocated the necessary funds and human resources to launch it into full developmental 
phase. 
I also took steps to make the EMCDDA Scientific Committee – until now an underused 
resource – more active in helping us improve scientific quality. In the future it will be more 
involved in tasks such as defining scientific standards and quality control of our outputs.
With regard to providing leadership and applying good management practice, I focused 
on human resources management, an area that was highlighted as weak in the last 
internal audit report of the European Commission. Recruitment procedures had lagged 
over the last year, so I concentrated on filling vacant posts and getting the working 
capacity of the Centre back to its full strength. I also launched the selection procedure for 
the key post of Head of human resources. I have set about developing new approaches 
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for staff appraisal as well as introduced initiatives to engender team spirit and increase 
staff motivation.
Based on the findings and recommendations of the audit report of the Internal Audit 
Service of the European Commission, I developed an action plan for improving 
administrative and financial processes. I also established close cooperation with 
Portuguese Authorities and with EMSA (the European Maritime Safety Agency) on matters 
such as the new building and to identify possible synergies.
With regard to building and improving partnerships, it was necessary first of all to bring 
clarity to our role as information provider and to imbue in the agency the importance 
of service provision. I intensified relations with the European institutions and agencies 
ensuring that our remit towards them and the results expected were clear. I also focused 
on strengthening ties with the Member States.
I would like to thank the members of the Management Board for the confidence they 
have expressed in electing me as Director. I would also like to thank my staff for the 
willingness they have shown to share in my vision to be an exemplary Monitoring Centre 
that delivers ever better and more relevant results.
Wolfgang Götz  
Director, EMCDDA
I
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Synthesis of main results compared with objectives of 
2005 work programme
The 2005 work programme continued to implement the EMCDDA’s three-year work 
programme (2004–2006) and its objectives were necessarily consistent with the longer-
term strategy. Work focused on three priority areas:
• to integrate fully the 10 new Member States into EMCDDA structures and activities; 
• to develop the EMCDDA’s information management capacity through a more efficient 
system for information storage and retrieval; and
• to improve the monitoring, reporting and dissemination of data through better tools, 
analysis and identification of client needs.
All activities were supported by a set of underlying principles which comprised: 
improving scientific standards; improving the visibility and recognition of the EMCDDA; 
focusing on core, cross-programme priorities and evaluating the relevance of these on 
an ongoing basis; increasing networking activities to draw out the potential of partners 
expertise; and improving relations with key partners, European institutions and bodies.
The main results are set out below by priority. A more detailed description of activities by 
programme area can be found in Chapter II.
Priority 1
Core tasks essential to implementing, developing and maintaining the existing 
instruments and mechanisms for data collection and analysis in the enlarged EU
Under this priority increased effort was required to process and analyse the data 
submitted to the Centre which has grown considerably both because of the increased 
number of countries providing data and because the quantity of data provided by each 
country has grown as reporting capacities have increased. Nevertheless, all routine 
reporting needs were addressed. And, although time for developmental tasks was less, 
the ongoing process of improving data comparability and reliability advanced. 
Particular attention was given to fully incorporating the 10 new Member States into 
EMCDDA activities. At each key indicator meeting, a special assessment was made of 
the needs of the new countries and this was supported with specific training activities 
and workshops. For example, statistical methods and collecting data on drug-related 
deaths were identified as a particular need for some countries and addressed in a 
Reitox academy workshop in Thessaloniki in June. A special workshop on estimation of 
problem drug use was held in Krakow in August with the specific aim of stimulating data 
collection.
The Reitox reporting system, which delineates the basic conditions for data monitoring 
and analysis, was further implemented in close collaboration with the Reitox community. 
New structured questionnaires agreed and implemented in 2005 included ‘Policy and 
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institutional frameworks’, ‘Reduction of drug-related deaths’, ‘Universal community 
prevention’ and ‘Selective and indicated prevention’. Sustained efforts were made 
to support members in meeting their reporting tasks through continued refinement of 
reporting tools and quality feedback on the information submitted.
Support was also provided to the candidate countries (Bulgaria, Romania and Turkey) 
to prepare them for participation in EMCDDA activities within the framework of the EU 
pre-accession strategy and in accordance with the relevant EU instruments (PHARE) and 
agreements with the concerned countries.
Priority 2
Further developing the EMCDDA data storage and retrieval system for 
quantitative and qualitative information reported by the national focal points 
and other relevant information providers
Work was stepped up on the data storage and retrieval system – a project pivotal to the 
future success of the Centre. An effective data management system is a prerequisite to 
moving towards a more efficient, output-driven approach and the system being developed 
will serve the strategic needs of the EMCDDA in data collection, information management 
and dissemination channels. This transversal project implies key changes in working 
methods within the EMCDDA and with the national focal points. 
During 2005, programme teams provided input on the definition and functions that such 
an information system should have and a full-time project manager was assigned to 
coordinate this project. In October, the Bureau approved a transfer of funds to boost the 
project’s implementation. A detailed set of technical specifications was elaborated and a 
call for tender launched in the Official Journal. The resulting offers were analysed and a 
contract signed with an IT company for its technical development.
Priority 3
Improving EMCDDA data reporting and dissemination on the drugs phenomenon
Work continued to promote an integrated approach to reporting, to improve the 
analytical quality of outputs and to produce products targeted at identified key 
information needs and audiences. 
The 2005 annual reporting package – the most comprehensive ever – reflected a better 
use of resources and more joined up approach to dissemination. The package comprised:
• the Annual report on the state of the drugs problem in Europe in 22 languages (printed 
and website);
• Selected issues (printed and website) on drug-related public nuisance, alternatives to 
imprisonment, and buprenorphine; 
• Statistical bulletin (PDF and website) presenting the full set of source tables on which 
the statistical analysis is based, the methodology used and over 100 additional statistical 
graphs;  
• Country data profiles providing a top-level, graphical summary of key aspects of the drug 
situation for each country;
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• National reports of the Reitox focal points giving a detailed description and analysis of 
the drugs problem in each country;
• Powerpoint presentation (22 languages) highlighting the main findings of the report.  
Further web-based resources were introduced and better systems of tracking their use 
were implemented. New products in this area included the Drug treatment overviews, 
a more user-friendly country and thematic presentation of EDDRA products and the 
Prevention and Evaluation Resources Kit (PERK). Content of existing websites was 
improved and further developed.
The EMCDDA’s findings on the drugs phenomenon were also disseminated through 
studies, scientific articles and abstracts, participation at international conferences and 
organisation of technical meetings. A full list of outputs can be found in Annex 3.
The impact of enlarged data sets from the newer Member States did mean that the 
regular out-turn of some products suffered. This had been set out as a possible scenario 
in the 2005 work programme. Despite this, we nevertheless managed to carry out much 
groundwork to improve data collection and quality and to invest in products that will 
come on stream in 2006 (cannabis monograph, policy briefings and thematic papers).
15
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Overview of activities by programme
Monitoring the drug situation
Objectives
The role of this programme is to collect information and report on the magnitude, patterns 
and trends in the drug situation. A range of epidemiological data sources, together with 
data from supply reduction measures and information on the illicit drug market, are 
used to provide an analysis of the nature and dynamics of the European drug situation. 
Collecting reliable data in this area requires ongoing work to improve the quality and 
comparability of the information on illicit drug use submitted to the Centre. The activities 
of the programme therefore are split between analytical and reporting activities, 
and more developmental tasks aimed at improving methodology and data collection 
approaches.
During 2005, considerable efforts were required to meet the growing challenge of 
processing and analysing the data submitted to the Centre. The volume of information 
now submitted has grown considerably both because of the increased number of 
countries providing data and because the quantity of data provided by each country is 
also growing as reporting capacities have increased. Thus a major activity is the cleaning 
and analysis of data submitted as part of the annual reporting exercise of the Centre. As 
well as information from routine monitoring findings, ad hoc research studies are also 
analysed to allow a more comprehensive basis for reporting on the drug situation. 
The other major area of work for this programme is to support the development of 
comparable methods for monitoring drug use in key areas (indicators) and to engage 
with national experts in an ongoing process of improving data quality and reliability. The 
five key epidemiological indicators, which have been formally adopted by the Member 
States are the principal responsibility here (1). These information domains are the 
foundations for much of the EMCDDA’s work to track trends in drug use in Europe over 
time. The implementation of the key indicators is also an explicit goal of the EU action 
plan on drugs (2005–2008). Progress has been made in developing reporting standards 
for core data on other important indicators for monitoring drug use including crime and 
supply data, market information, measures of drug availability, and surveys of drug use 
in special populations and the detection of emerging trends.
Activities and results 
Overview
Epidemiological data from national reports and other sources concerning 29 countries (all 
Member States of the European Union, candidate countries and Norway) were analysed 
and synthesised to provide a comprehensive overview of epidemiological data for the 
EMCDDA’s 2005 Annual report. To support the top-level analysis presented in the Annual 
report, all data tables used, methodological notes, more detailed analysis and supporting 
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(1) The five indicators are: Prevalence and patterns of drug use among the general population 
– population surveys; prevalence of problem drug use; demand for treatment by drug users; drug-
related deaths and mortality among drug users; and drug-related infectious diseases.
graphics were made available in an accompanying statistical bulletin containing over 
200 data tables. The statistical bulletin allows the data collected by the EMCDDA to be 
available to a wide European and international audience and it is now being used as a 
resource for scientists and students. 
In 2005, the Annual report maintained and further developed the integrated approach 
launched in 2004. Chapters were structured either around substantive topics or around 
specific drugs. The programme contributed to the overview of the drug situation, chapters 
3 to 8 (cannabis, amphetamine-type stimulants, LSD and other synthetic drugs, cocaine 
and crack cocaine, heroin and injecting drug use, crime and prison issues) and to the 
selected issue on buprenorphine.
Preparatory work was undertaken to assemble the necessary information for the selected 
issues that will be addressed in the 2006 Annual report. This included a data analysis 
exercise on gender differences in drug use and a special data-collection exercise focused 
on cocaine.
In 2005, particular attention was given to the further integration of the newer Member 
States and the candidate countries into the reporting activities of the Centre. At each 
key indicator meeting, a special assessment of the needs of the new countries was made 
and this was supported with some specific training activities and workshops, which 
were closely coordinated with the Reitox academy. Statistical methods and collecting 
data on drug-related deaths were identified as a particular need for some countries 
and addressed in a Reitox academy workshop in Thessaloniki (in June). In Krakow (8–9 
August), a special workshop on estimation of problem drug use was held with the specific 
aim of stimulating data collection. Detailed assessment of national reports and standard 
tables delivered by Bulgaria, Romania and Cyprus was also undertaken as preparation 
for a Reitox academy workshop on crime/supply aimed at facilitating improvements in 
national reporting on these topics. A Reitox academy on collecting treatment demand 
data was also organised with the Romanian focal point.
Data analysis: improving efficiency and developing new approaches and tools
The data collected, validated and processed for the Annual report were incorporated 
into the Epidemiological Information System on Drug Data (EISDD). In parallel, work 
continued on defining and setting up a computer-based data storage and retrieval system 
for qualitative and quantitative information in different formats. The EISDD meta-database 
was restructured to provide a better communication interface with the new, subsequent 
link-up to Reitox website and uploads. The old system for linkage to internal server 
bases with physical copies of standard tables disappeared completely in the 2005 data 
collection exercise, and was replaced with a new interactive data accessing facility. For 
the first time data introduction interfaces for crime/prison data were made available and 
these data sets moved into the EISDD, which also benefited from the development and 
implementation of a new table-update system. The new online interface for data collection 
for the Centre was fully implemented for standard table 1 (population surveys) and used 
as a basic model for informing the design of the new set of online interfaces that will 
be developed from 2006 onwards within the new data storage and retrieval system. 
As part of the work to improve the statistical bulletin, a set of visual basic programmes 
for automatic production of graphs and tables were developed. And for the first time 
a set of specific data profiles for each country was produced. As part of the work to 
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assist countries with developing analytical capacity, work was started on a spreadsheet 
calculator for capture-recapture estimation of drug-using populations. 
Key indicator: Prevalence and patterns of use among the general population (population 
surveys) 
Data from this indicator is a mainstay of the EMCDDA reporting exercise so a particular 
priority in this area was to collect, improve and analyse information from the new 
Member States so that they could be better represented in the 2005 reporting exercise. 
This was facilitated by the new online interface for data collection, the standardisation of 
the survey methodology in general, and the high level of implementation of the European 
Model Questionnaire EMQ) by the new Member States. 
The improvement of analysis was promoted by the presentation of the final results of the 
project CT.03.P1.200 (Sumnall, H.) during the annual expert meeting. A detailed analysis 
of data available in the EMCDDA epidemiological database (EISDD) was conducted for 
the forthcoming EMCDDA monograph on cannabis. 
Key indicator: Problem drug use
Work on the problem drug use (PDU) indicator has concentrated on further developing 
the conceptual framework of problem drug use (including the EMCDDA definition). This 
is necessary in the light of recent changing trends in other indicators, such as population 
surveys and treatment demand that indicate strong increases in some drugs that may 
presently not be adequately measured by the agreed methods and guidelines from the 
EMCDDA on PDU. In addition, national definitions and coverage of estimates were 
analysed and have allowed problem drug use estimates to be separated into estimates 
of problem heroin use and problem stimulant use (as far as available), in addition to the 
estimates of overall problem drug use. 
This ongoing developmental process has also resulted in an update of standard data 
reporting tables 7 and 8, which now explicitly ask for separate PDU estimates to be 
provided by main group of drugs and route of administration (opiates versus stimulants, 
non-injecting versus injecting).
At the EU expert meeting of 20–21 October, sessions were held on prevalence 
estimation, estimation of incidence and analysis of drug careers and the EMCDDA data 
quality/data entry system. In addition, national representatives presented a range of 
national level analyses such as how to link data from general population surveys to the 
PDU estimates from indirect methods. 
Considerable efforts were also made in 2005 to clean and reorganise the historical 
database on PDU, which resulted in a significant improvement in quality and efficiency of 
data processing. 
Key indicator: Treatment demand
The activities carried out in 2005 concerning the Treatment demand indicator (TDI) 
focused on enhancing data quality, with particular attention paid to improving data 
coverage and harmonising of data collection between the countries. Efforts were also 
made in the integration of the new European Member States and the candidate countries 
into data collection and reporting systems. 
19
Chapter 2 
The annual expert meeting on TDI was organised on 22–23 September 2005 in three 
sessions: the first on data quality and methodological aspects, the second on proposals 
for future developments, and the last was devoted to updates on ongoing projects. 
In addition, as has been the case for the last four years, there was a session with 
international organisations where experience and data results from Latin American 
countries were presented.
The main outputs from data collected through the TDI were the sections on treatment 
demand in the Annual report and the statistical bulletin and the selected issue on 
buprenorphine. The background work for data analysis included data checking, data 
cleaning and data entry into the EISDD. Two further analyses of TDI data concerned a 
breakdown of treatment data by gender, which was published in a technical data sheet, 
and an analysis of living conditions among treatment clients, which will be disseminated 
in a policy briefing in 2006.
Preparatory work for the cannabis monograph was undertaken. A contract with an 
external consultant was launched in December 2004 and the first draft was ready at 
the end of 2005. Data from the eastern countries was analysed with countries experts, 
which will result in a technical data sheet in 2006. A toolkit on the TDI, carried out in 
collaboration with the UNODC and targeted at professionals and scientists working on 
treatment demand information in Europe and outside Europe was prepared. A working 
group on gender data was set up in order to analyse data on gender among treatment 
clients. The working group is composed of five countries that will contribute to a scientific 
article on treatment data with a breakdown by gender (Austria, Czech Republic, Greece, 
the Netherlands, Switzerland).
Key indicator: Drug-related deaths (DRD) and mortality among drug users
During 2005, considerable emphasis was placed on consolidating data collection from 
the new Member States, and on implementing the common definitions. This work focused 
along two lines: the annual Reitox data collection, which required extensive discussions 
with focal points and experts, and the detailed data collection of cases foreseen in the 
DRD protocol (through external contract CT.04.P1.359). 
In addition, the DRD protocol was updated to harmonise the ICD classification with Reitox 
standard tables regarding substances involved in the fatalities recorded. Furthermore, to 
meet the need to have more precise information on toxicology in drug deaths a specific 
extra table was developed in cooperation with several experts and its field trial approved 
by the Heads of focal points.
In the annual expert meeting (23–25 November) considerable stress was put on 
improving analysis of drug-related mortality in two areas. One was the total mortality 
related to drug use (overdoses and other causes) within a particular country by 
combination of information from mortality cohorts, mortality registries and estimations of 
prevalence of problematic use. A workshop was dedicated to this topic. The other area 
was based on an analysis of the impact of overdose mortality at population level in all 
the EU Member States, and proportional mortality of overdoses and AIDs deaths (Vicente, 
J. and Matias, J.). This analysis required combination of data from the EMCDDA, Eurostat 
(causes of deaths) and EuroHIV.
In several cases, the link between epidemiology and interventions was reinforced (Reitox 
academy, DRD expert meeting, Belfast conference on the reduction of drug-related harm).
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Key indicator: Drug-related infectious diseases
In 2005, activities on the drug-related infectious diseases (DRID) indicator focused on 
consolidating and improving the basic data collection system. This entailed reviewing 
and updating guidelines, data collection instruments and data organisation, storage and 
retrieval. An important part of the work consisted of ongoing detailed communication 
with the individual Member States on the data provided. The latter included the 
organisation of a two-day Reitox academy workshop in Malta.
An important activity was the organisation of the annual EU DRID expert meeting on 
10–11 October, which convened over 50 experts who discussed common activities (see 
below) and presented their national work within the framework of the EU DRID indicator. 
The expert meeting was organised in the same week as the expert meeting on problem 
drug use, thus allowing exchange of experiences and experts between both projects.
During 2005, the existing basic draft guidelines (EMCDDA 2000) were further developed 
by starting work on a more detailed protocol. This protocol provides more guidance on 
the primary data collection process than the draft guidelines. This work was done in close 
collaboration with the Greek national focal point (contractor) and the EU expert group 
on DRID. As an important part of the protocol, a draft questionnaire was developed 
with core item sets for both routine data collection (reduced set) as well as for surveys 
among IDUs (expanded set). A planning meeting was held from 30 June to 1 July at the 
EMCDDA with a small editorial group of key experts. The protocol was further discussed 
during and after the EU expert meeting on 10–11 October. This work also resulted in 
an important update of standard table 9, which included the introduction of a new data 
sheet on risk behaviour (test version). 
A project on ‘laboratory surveillance of HCV in young people’ was initiated, which is 
expected to provide data on HCV as an indicator of infection as well as of injecting 
drug use in the general population (contractor HPA, UK). These data should become 
an important complement to the currently available data on HCV-ab prevalence in IDU 
samples and notifications of cases of viral hepatitis C. 
Additional activities involved the start of a study on ‘identifying protective factors in 
countries with low HIV/AIDS prevalence rates in drug users’, following a request to the 
EMCDDA by the Member States through the EU drugs action plan (2005–2008; objective 
43 point 2). Initial format and funding possibilities for the study were explored at the EU 
expert meeting and through a call for interest to which experts from nine countries and 
from WHO responded and which is being further developed during 2006.
Much effort has been invested in cleaning and reorganising the historical database at 
the EMCDDA resulting in a significant improvement in quality and efficiency of data 
processing.
Crime, markets and supply data
Topics of interest in this area are crime, prison, global situation on production/trafficking, 
overview on trafficking, national level data on seizures, price, and purity of street drugs. 
Data are collected through the Reitox network (standard tables 11 to 16) and during 
2005 reporting tools were under review resulting in the revision of the guidelines 12, 14 
and 16. In addition to information provided by Reitox data, the EMCDDA maintains a 
close working relationship with Europol, and also uses the data available from UNODC, 
CND and INCB in order to inform its reporting.
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An expert meeting on drug availability from population surveys was held on 29 June 
which led to the drafting of a final report of the EMCDDA project to develop a new 
module on drug availability in population surveys (4 volumes). Also during 2005, a 
review of all historic data submitted on price and purity/potency (standard tables 14 and 
16) was undertaken as part of the work to validate and check the historical data set data 
prior to entry into EISDD. A review of all historic data submitted on seizures of cannabis 
products, by product and by seizing agency; validation and checking; construction of 
time series for all cannabis products (plants, herb, resin) and by seizing agency (all 
agencies, police, customs) was also undertaken as part of the preparatory work for the 
EMCDDA cannabis monograph.
European youth epidemiology data
Work in this area describes and analyses emerging trends and drug trends among youth. 
Data are assembled from youth and school surveys reported by Reitox or identified 
through other networks, international reports and journals. 
In 2005, data from youth and school surveys were analysed for the Annual report. 
Collaboration with ESPAD (the European School Project on Alcohol and Other Drugs) was 
intensified, and a joint project to analyse gender differences among school students was 
set up. The E-POD (European Perspectives on Drugs) project to detect, monitor and track 
emerging trends was elaborated and a reporting form and literature review for an E-POD 
case study on hallucinogenic mushrooms were introduced. Also in 2005, the results of 
an exploratory study on the potential of youth media as a new source of information 
to improve capacity to understand and quickly respond to emerging drug trends were 
published in a thematic paper. 
Cooperation
There has been cooperation with other European and international bodies, including: 
• Eurostat and Sanco (DG public health – health monitoring) of the European Commission. 
Activity was continued, in particular in the area of population surveys, drug-related deaths 
and mortality among drug users, and drug-related infectious diseases. The EMCDDA also 
participated in meetings to help SANCO with the development of a new pan-European 
public health portal.
• The ESPAD survey group. In 2005, closer cooperation was realised with the ESPAD 
network who were reporting on the new round of their study. EMCDDA conducted a number 
of joint meetings with ESPAD and included an analysis of the new ESPAD data in the 2005 
Annual report.
• The UNODC (United Office on Drugs and Crime) for streamlining international reporting, 
treatment demand and development of international epidemiological systems, and for 
collaboration and coordination on activities related to drug-related data on crime and supply 
and on a manual on treatment demand data collection.
• WHO (World Health Organisation), for drug-related deaths, treatment demand and drug-
related infectious diseases indicators. 
• The Pompidou Group of the Council of Europe, on indicator development and polydrug 
use. 
• Europol for crime and supply data (see section on Joint action for further information on 
collaboration with Europol).
• EuroHIV and UNAIDS for the drug-related infectious diseases indicator.
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Monitoring responses to drug use
Objectives
The main objective of this programme is to collect, analyse and disseminate information 
on national policies, availability and quality of interventions and services related to:
• prevention of drug use, including universal and selective prevention; 
• harm-reduction responses to the drug situation, i.e. prevention of infectious diseases 
and acute drug-related deaths; 
• prevention of drug-related crime, in particular assistance to drug users in prisons and 
alternatives to prison.
The focus in 2005 was to improve and consolidate the quality of information via 
specific reporting instruments. Quality control and feedback, training and competence 
development – particularly in evaluation of interventions – were other aspects of the 
2005 work on quality assurance. Accordingly, the expected outcomes were more and 
better online and paper reports, web publications and thematic analyses, as well as 
presentations in different fora. 
Activities
Data collection and analysis
The 2004 Reitox national reports as well as standard tables and structured questionnaires 
were processed and analysed for the 2005 annual reporting package. Structured 
questionnaires on ‘Reduction of acute drug-related deaths’, ‘Universal community 
prevention’ and ‘Selective and indicated prevention’ were implemented for the first time. 
The overview on the coverage, organisation and quality of school-based prevention 
improved in most Member States.
A structured questionnaire on alternatives to prison for drug using offenders was 
prepared and approved by the Reitox focal points. An expert meeting on low-threshold 
data collection, in collaboration with the EU-funded ‘Correlation project’ included a 
review of availability of data from low-threshold agencies and of reporting tools used.
A survey on health and drug services in prisons in the 10 new EU Member States 
was implemented by a contractor, the German Wissenschaftliches Institut der Ärzte 
Deutschlands (WIAD). The results were fed into a prototype database on prison and 
health, developed as a joint project of the EMCDDA and WHO, Regional Office for 
Europe.  
The programme contributed to the qualitative evaluation of national reports and 
cooperated with Reitox and other programmes to streamline information collection within 
the Centre. It contributed to preparatory work on the development of an electronic data 
collection and retrieval system. Two Reitox academies – on collection of harm-reduction 
data and on collection of information on selective prevention and universal school-based 
prevention – were organised.
A technical contract with CRPHT was concluded, which updated the EDDRA offline tool 
and database to include the Member States that joined the EU in 2004. An updated 
version of the EDDRA questionnaire was produced and distributed and the national 
EDDRA reporting guidelines for 2005 updated accordingly.
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Outputs and visibility
Annual reporting
The 2004 Reitox national reports as well as standard tables and structured questionnaires 
were processed and analysed for the EMCDDA annual reporting exercise. Information 
from other sources was collected, classified and analysed. Texts, tables, graphics and 
maps were drafted for the Annual report printed and online versions as well as a selected 
issue on ‘Alternatives to prison’.
Websites  
The part of the website dedicated to these activities was continuously updated. A range 
of reports, online articles, tables and graphics, as well as external links were put on 
the web. New prevention definitions (universal-selective-indicated) and evidence-based 
criteria were promoted through the website.
A call for submission of hepatitis C prevention projects and supporting their inclusion 
in EDDRA database was initiated and a new web-based ‘hepatitis resource area’ was 
conceptualised.
Visits to the Evaluation Instruments Bank (EIB) increased substantially with a proactive 
promotion strategy. EDDRA expanded considerably and 88 entries and 41 updates were 
processed. EDDRA online information was regularly updated, a monthly e-newsletter 
distributed and a marketing fact sheet on EDDRA launched. The annual meeting of 
national EDDRA managers was held in September. A survey among Management Board 
members confirmed that reliable information on good practice such as that presented in 
EDDRA is important for decision makers. 
The Prevention Evaluation Resources Kit (PERK) is a web-based training module that 
links prevention models and components to the principles of prevention quality and 
evaluation (EDDRA) and to the according evaluation variables (EIB). It was published 
in the EMCDDA website at the end of 2005 and immediately attracted a high level of 
interest. It is being translated into Greek, French, Bulgarian, German and Portuguese by 
the respective focal points. 
Cooperation with external partners
Programme staff participated in the coordination group of the DG Sanco project on 
the evaluation of implementation of Council recommendation on reduction of drug-
related harm of 18 June 2003. Considerable technical input was given to the project: 
identification and provision of relevant EMCDDA datasets; advice about the interpretation 
of these data; feedback to all products related to the implementation of the project; 
participation at project meetings; hosting a consultant visit as well as provision of advice 
on further data sources and scientific research literature. 
The close cooperation with WHO, Regional Office for Europe, was maintained and a 
common action plan in the framework of the existing Memorandum of Understanding 
was signed. Cooperation with this programme is mainly in the area of prison and 
health with a joint database (see above) and participation in the WHO Health in Prison 
Project (HIPP) Task Force. Staff also participated at the joint WHO/DG Sanco Ministerial 
conference on mental health and follow-up events. Together with the epidemiology team, 
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two meetings on HIV and hepatitis co-infection clinical protocols and treatment protocols 
for IDUs were co-organised with WHO. 
Other partnership activities included:
• participation in the Pompidou Group platform on ethics;
• advisor to the first ‘European drug abuse prevention trial’ (DAP), with eight European 
partners. Development of a new state-of-the-art European prevention programme, evaluation 
instruments and research design;
• advisory board of the DG Sanco project on health and social exclusion (Correlation 
network); hosting pre-launch meeting in June;
• advisory board of the ROVAID project for integrated assistance for women drug users 
during pregnancy or with children;
• member of the European Network on Drug Services in Prison (ENDSP) and Central and 
Eastern Europe Network on Drug Services in Prison (CEENDSP) steering groups;
• drug prevention seminars for the SCAD (Southern Caucasus against drugs) programme 
in Tbilisi, Georgia and for the BUMAD (Belarus, Ukraine and Moldova against drugs) 
programme in Chisinau, Moldova.
Implementing the 1997 EU joint action on new synthetic drugs and 
Council Decision 2005/387/JHA  
In May 2005, Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk assessment and control of new psychoactive substances (2) (the Decision) 
entered into force. This Decision established a mechanism for the rapid exchange of 
information on new psychoactive substances appearing on the European drug scene. This 
Decision replaced and broadened the scope of the 1997 Joint action on new synthetic 
drugs. 
Objectives
The priority objective was to ensure that the specific tasks stipulated by the new Council 
Decision were given a high priority in order to achieve a smooth transition from the Joint 
action to the mechanism set up by the Decision.
Activities and results
To ensure a smooth transition from the Joint action to the mechanism set up by the 
Decision, and to operationalise its implementation, specific arrangements were made 
to facilitate the exchange of information between the responsible institutions and their 
respective networks. These included a new reporting form, definition of criteria, and 
cooperation with the European Medicines Agency (EMEA) and the UN system.
As requested by Article 3(g) of the Decision, an EMCDDA–Europol reporting form was 
designed as an official reporting tool for notification of a new psychoactive substance 
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(2) Council Decision 2005/387/JHA on information exchange, risk assessment and control of new 
psychoactive substances was published in the Official Journal of the European Union on 20 May 
2005 (L 127/32-37) and took effect the following day, i.e. on 21 May 2005.
under the Decision. The reporting form is a concise document, appropriate both for the 
Reitox national focal points and for the partner Europol national units. The EMCDDA 
and Europol have pledged that, as a rule, all information that they officially receive from 
Member States through reporting forms shall be immediately transmitted to all partners. 
To provide for a consistent approach and to help ensure a high degree of transparency of 
the decision-making process under the information exchange mechanism of the Decision, 
the EMCDDA and Europol have elaborated a set of criteria to be considered in order to 
justify the collection of further information that will lead to the production of a Joint report 
(Article 5 of the Decision).
The EMCDDA and the EMEA agreed to establish stronger cooperation with the 
pharmacovigilance system. In addition, it was agreed that it was the responsibility of the 
national focal points to establish links with the relevant national competent authorities 
(NCAs) in their country to initiate cooperation with the pharmacovigilance system at a 
national level. 
To obtain the information requested in Article 5.2(e), the EMCDDA established a 
permanent communication channel with the Department of Medicines Policy and 
Standards, which prepares the Expert Committee on Drug Dependence (ECDD) of the 
World Health Organization (WHO) Article 5.2(e).
During 2005, 14 new psychoactive substances were officially notified within the early-
warning system.  These were all psychotropic substances (synthetic drugs) similar to those 
listed in Schedule 1 and 2 of the 1971 UN Convention. The substances notified by the 
Member States to the EMCDDA/Europol after the Decision came into effect, i.e. after 
21 May 2005, would have been notified under both the current and the previous legal 
instrument – the 1997 Joint action and Council Decision 2005/387/JHA. 
In August 2005, Europol and the EMCDDA examined the information collected on 
mCPP through a joint assessment based on the predefined criteria. It was agreed that 
the information collected so far merited the production of a Joint report as stipulated by 
Article 5.1 of the Decision. The conclusions and recommendations of the Joint report 
were prepared by the two responsible organisations – the EMCDDA and Europol – in 
consultation with the EMEA. Thus, the first Joint report under the new legal framework 
was submitted to the Council, the Commission and the EMEA on 28 October 2005 within 
the deadline stipulated by the Decision. 
In view of the new experiences and the lessons learned through the implementation of 
the 1997 Joint action and the Decision, the EMCDDA has undertaken to prepare new 
guidelines for the information exchange/early warning system. The guidelines aim to 
assist the early warning system partners in introducing the new working methods taking 
into account the individual countries’ specific needs and situations. In this context, the 
EMCDDA is attempting to develop a more integrated approach with Member States to 
enable the collection, monitoring and exchange of information on emerging trends in 
the use of existing substances and on possible public health-related measures. To explore 
the feasibility of implementing an emerging trends monitoring system, a specific cross-
programme pilot project ‘Detecting, tracking and understanding emerging trends’ was 
launched.
In order to raise the awareness of the new legal instrument and its added value, an 
awareness-raising promotional brochure was prepared. 
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The EMCDDA database on new drugs was internally installed and operationalised, 
thereby providing structured access to the specific information collected through the EWS 
and enhancing the internal capacities to store/retrieve data and to produce reports. 
Through training activities, special attention was given to assist the new Member States 
and the accession countries in the development of their national EWSs.
Monitoring national and Community strategies and their impact 
Objectives 
This programme’s work aims to monitor and describe policies, their framework and their 
relevant context, to contribute to policy analysis, and to contribute to policy evaluation. 
Two main groups of activities have been developed in order to achieve this. Monitoring 
and analysis activities concentrate on coordination mechanisms, national strategies, 
European and national legislation, public expenditure and evaluation schemes and tools, 
and treatment and social integration responses. The second group of transversal activities 
focus on coordinating and designing the EMCDDA’s contribution to the evaluation of the 
EU strategy and action plan.
Activities and results
In 2005, effort focused on consolidating work launched in earlier years and the 
continued development of the areas mentioned above. The programme provided a 
substantial input to the Annual report – in particular, Chapter 1 on policy developments 
and the sections on treatment responses. It also drafted the selected issue on ‘Public 
nuisance’. Staff from the team were also fully involved in the launch of the Annual report 
across Europe.
National policies, coordination mechanisms and public expenditure
In the area of national policies, one of the most significant achievements was the 
consolidation and streamlining of the data collection process. This comprised the testing 
and adoption of the structured questionnaire on ‘Policy and institutional framework’, 
which is a new standardised and pan-European tool for data collection and implemented 
in the latest Annual report guidelines (thus results are expected in November 2006).
Further outputs included a paper on the confiscation of assets, which was prepared for 
the National Drug Coordinators meeting and a chapter on policy and laws drafted for 
the EMCDDA monograph on cannabis. 
To consolidate the work in the coordination area, an external study on the effects of 
coordination in the field of drugs in four countries was coordinated and revised. In 
preparation for work in 2006, a call for tender for a literature review on the impact of 
the modification of drugs laws was launched and contractor selected. 
Demonstrating the capacity of the EMCDDA to respond to high-level external requests, a 
‘Position paper on the modification of the Italian law’ was prepared and delivered to the 
Italian Senate. In December, following publication of the post, a new project manager 
was selected to concentrate on this area of work from 2006.
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One of the main accomplishments in the area of public expenditure was the drawing up 
of a matrix on all aggregates of public expenditure (direct, indirect, supply, demand) 
relating to the drugs phenomenon in the EU. Using this matrix, a preliminary document 
was written to present the principal issues and subjects to be discussed when developing 
a methodology for collecting standardised data on public expenditure on drugs. A 
paper on drugs expenditure in Europe was also revised and finalised for publication in 
the scientific journal Addiction. Thus, after a long but fundamental phase of conception 
and study, the EMCDDA is now ready to begin drafting an agreed standardised data 
collection instrument for national focal points. The selection procedure for the new project 
manager for this area was also completed.
National and EU legal developments
With regard to the activities of the legal team, there was continued improvement of data 
collected and presented by the European Legal Database on Drugs (ELDD). The ELDD 
now holds over 750 original legal texts at EU and national level; the publication of 
Slovenia in 2005 completes the representation of all 26 EMCDDA member countries in 
ELDD. To streamline the processes of data collection and updating studies, the database 
was restructured to provide the more user-friendly sections of ‘Topic overviews’ and 
‘Legal reports’. At a glance, the topic overviews give both textual and tabular synopses 
of the most frequently demanded topics within the sphere of drug law, at international, 
European and national levels, and are essential tools for policymakers, researchers and 
the media. Four of the topic overviews (covering classifications, possession, trafficking, 
and treatment alternatives to prison) were fully updated and a completely new overview 
was published on needle and syringe programmes. More have been drafted, for example 
on cannabis, drugs and the Internet, mushrooms, and workplace drug testing; the latter 
was the central theme of the year’s annual Legal correspondents meeting. At the request 
of the Legal correspondents, the comprehensive substances table is also being updated. 
In line with these improvements of data presentation, a new information system on EU 
drug activities was designed and will be available online in 2006. The objective of this 
tool is to gather in one place information on EU legal instruments, adopted or pending, 
on EU activities and on EU policies towards the various aspects of the drug phenomenon 
and the control of illicit substances. The information system will also provide relevant 
information on the evaluation process of the EU action plan on drugs and on the tools 
developed and implemented at EU level. For the first time, information on the action of 
the EU in the field of drugs will be gathered in an organised structure and will provide 
users easy access to complete, detailed and synthesised information.
Legal information gathered by the ELDD was used to answer the increasing needs of 
external enquiries. The close cooperation between the legal team, the network of Legal 
correspondents, and the Drugs coordination unit of the European Commission, has 
proven to be a rapid and efficient method of providing information on drug asset funds 
for the National coordinators meeting, legal hemp cultivation following a request from 
Cyprus, recreational facilities licensing for the Lithuanian national focal point, legal status 
of mushrooms for the British Government, etc. The team provided regular analysis and 
follow up of the proposals made on the recast of the EMCDDA regulation, and answered 
ad hoc internal requests, including briefings on programmes implemented by DG Justice 
Freedom and Security and on recent EU legislation on drugs. 
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The considerable increase in the legal team’s contribution is also visible in the EMCDDA 
Annual report process. In 2005, the team played a significant part in the two selected 
issues on public nuisance and alternative to prisons, and it was central to the drafting of 
the 2006 selected issue on licit and illicit drug policies. In preparation for the selected 
issues for the 2007 Annual report, it drafted guidelines on drugs and driving and made 
a significant contribution on drug use among very young people. Finally, cooperation 
has continued with relevant partners, with the legal team taking part in several important 
meetings, such as the Horizontal Drugs Group, Pompidou Group (testing in schools, and 
road safety), Europol (‘2005 organised crime threat assessment report’) and Eurojust 
(European criminal intelligence model). 
Drug-related treatment and social reintegration
In the areas of drug-related treatment and social reintegration, the two new structured 
questionnaires were completed to a generally high standard by 27 countries, following 
the resolution of various problems. Both information sets were comprehensively analysed, 
and as a result two overview reports were drafted. These reports, making full use of data 
provided by the Reitox network, will be further developed and published, allowing for 
the first time a complete overview of the situations of drug-related treatment and social 
reintegration in the enlarging European Union.
28 ‘Drug treatment overviews’ (presented by country) were harmonised according to a 
new template that was developed at the start of the year. After finalisation in consultation 
with the national focal points, the new EMCDDA web area covering treatment and social 
reintegration was launched on 26 June, International day against drugs – six months 
earlier than planned. 
The EMCDDA manual ‘Drug treatment evaluation guidelines’ was finalised. This is an 
invaluable tool for researchers and professionals, and is of assistance to policymakers, 
who wish to evaluate treatment programmes in order to improve their treatment policies, 
availability, and coverage.
In 2005, 23 new entries were published in the EIB (Evaluation Instruments Bank) to 
assist in evaluating responses to drug use. Although some entries were translations of 
instruments already published, they included seven completely new instruments, including 
the ‘Blood borne virus transmission risk assessment questionnaire’. This is particularly 
significant, being the first instrument in the EIB contributing to the evaluation of harm-
reduction measures. Entries also included instruments in three languages, which had not 
earlier been present at the EIB site, increasing its usefulness at the local level. Another 
enhancement was the new linkage of entries between the EIB and EDDRA. For the first 
time, the instruments used to evaluate an EDDRA entry (‘Searching family treasure’, from 
Portugal) were published in the EIB, with reciprocal hyperlinks in each database to allow 
the user to easily consult both the project and its evaluation tools. During the year, 10 EIB 
newsletters were submitted to the EIB mailing list, keeping subscribers regularly updated 
about the publication of new instruments and/or other news.  
Contribution to the EU action plan (2005–2008) and interinstitutional representation
Transversally, the programme coordinated the EMCDDA’s contribution to the work of the 
European Commission on the evaluation of the new action plan on drugs (2005–2008). 
To begin with, assistance was given in the drafting of the action plan itself, answering 
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questions from Member States and the European Commission within the Horizontal 
working party on drugs on the technical feasibility and scientific relevance of the 
indicators and evaluation tools mentioned therein. Since then, the programme has worked 
with the Commission on establishing the first roadmap for the evaluation of the action 
plan, in the framework of the annual review of implementation, for which the Commission 
is responsible. The EMCDDA is also already involved in the contribution to the final 
impact assessment scheduled for 2008.
Furthermore, the report on the evaluation processes and methodologies established in 
six Member States to assess their strategies or action plans, which is to be published in 
2006 was fine-tuned. This is a tool to help Member States evaluate their own strategy 
and/or for policymakers considering evaluating their policy.
Other aspects of inter-institutional representation included making presentations at four 
meetings of the Council’s Horizontal working party on drugs, and also at a number of 
related meetings, showing increased visibility and consultation of the EMCDDA on drugs 
matters in Europe.
Reitox and Enlargement 
 
The Reitox and Enlargement unit underwent some significant changes in 2005 that has 
had an impact on its mission and activities. As a consequence, the unit launched an 
internal reflection process aimed at redefining its mission and tasks within the framework 
of the new organisational structure of the Centre. The new organisation of the work of 
the unit is a direct result of this process and is reflected in the presentation of its activities 
below. 
Activities in 2005 covered two main areas: management of the Reitox network and 
Enlargement activities (which were extended at a later stage to include international 
cooperation and relations with international organisations).
Reitox network
Network management and grant agreements
Work in this area concentrated on implementing the grant agreements, which required 
particular attention, as it was the first time that the 10 new Member States submitted 
financial and activity reports. Another factor that influenced implementation of the grant 
agreements was the decision to follow the recommendations of the Court of Auditors and 
to allow the payment of the first instalment of the 2006 grant only after the closure of the 
2005 grant file. Although most countries provided the Centre with satisfactory reports 
and documents, for some countries it took more time than expected. As a consequence, 
the Reitox unit, in cooperation with the EMCDDA financial section, has taken measures 
to ensure the situation is better monitored, and to improve the speed and quality of the 
processes.
Quality assurance and capacity development
Extensive quality feedback was prepared and presented to the national focal points in 
May 2005, and served as background for the technical meeting organised 18–20 May 
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2005 on national reporting. The objective of the meeting was to receive feedback from 
focal points on the format of the quality feedback and discuss any changes, as well as 
to familiarise focal points with the new Reitox extranet. In addition, focal points were 
introduced to the new reporting tools for the 2006 reporting cycle.
In September 2005, the Quality assurance manager proposed and discussed with project 
managers new quality criteria to be used for the validation phase of standard tables. 
These were agreed upon and subsequently incorporated into the EISDD.
Ongoing reflection on the reporting guidelines and processes was followed up at the 
Head of focal points meeting in November 2005. Working groups were organised to 
discuss any problems/requests for changes in the national report guidelines as well as 
any changes to existing standard tables and structured questionnaires. The new selected 
issue guidelines were introduced and reviewed, and the guidelines for 2006 reporting 
were adopted. The reporting guidelines were improved in 2005 through a revision of the 
first chapter and the inclusion of a chapter on interpretation of trends and survey results 
in order to better instruct and orient focal points. 
A quality assurance policy document, which includes the various activities carried out at 
the Centre within the framework of quality assurance, was drafted for adoption by the 
Directorate of the EMCDDA.
The new online information source presented in the form of ‘Country situation summaries’ 
(http://profiles.emcdda.eu.int), which are illustrated via an enlarged European Union 
and individual country maps were updated and published in November 2005. These 
brief and concise overviews on the drug situation in the old and new EU Member States 
and Norway are published in the respective national languages as well as in English. 
They are compiled from national reports and standard tables, submitted through Reitox 
and produced in collaboration with the national focal points. The country situation 
summaries include all 25 Member States and Norway. 
Capacity development activities were also refined in 2005. According to the proposal 
made in the February meeting of the Heads of focal points, Reitox academy activities 
were reorganised as follows: a limited number of academies at European level involving 
all countries; some update sessions reserved for national experts participating in the EU 
expert working groups; and the promotion of cluster training initiatives and of national 
academies. This new approach was adopted also for the training activities organised in 
the framework of the Phare project with Bulgaria and Romania.
In order to improve the quality and relevance of training activities organised within the 
framework of the Reitox academy and the Phare project, a project manager from a 
scientific department is closely associated to each academy to assist with the contents, 
methodology and selection of trainers. 
After an analysis of the training needs for all 26 national focal points, combined with 
a screening of the areas of work where reporting instruments still had to be presented, 
three Reitox academies were organised at European level (all materials are available on 
the Reitox academy extranet, http://academy.emcdda.europa.eu):
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• Reitox academy on ‘Relations with the media’, Budapest, 1–3 June 2005
• Reitox academy on ‘Harm reduction core data’, Lisbon, 26–28 September 2005
• Reitox academy on ‘Prevention core data’, Lisbon, 14–16 December 2005
The following national Reitox academies were organised in Valletta:
• Reitox national academy on the ‘Early warning system’, October 2005
• Reitox national academy on the ‘Drug-related infectious diseases indicator’, November 
2005.
The Reitox academy on ‘Relations with the media’ was organised in close cooperation 
with the Communication unit and one of the practical workshops was more specifically 
dedicated to the preparation of the launch of the EMCDDA Annual report, including the 
preparation of some national launches.
Enlargement activities
With the extension of the scope of the Reitox unit’s work, activities implemented in this 
area covered international cooperation and technical cooperation.
The coordination of international cooperation aims to help the EMCDDA to better achieve 
its objectives within the area of international relations. A better-balanced approach 
coordinates internal information and data requirements, necessary external presence 
and visibility, enlargement needs and, finally, ad hoc requests from third countries and 
organisations. The unit is also responsible for the coordination of official visits paid to the 
Centre. 14 such visits took place between May and December.
A revision of the cooperating frameworks with the key international partners was 
launched. New cooperating provisions were agreed with Europol and with the Pompidou 
Group of the Council of Europe. The Centre participated in several statutory meetings 
convened by these organisations and by Interpol, the WCO and CICAD-OAS. The 
Centre also participated in the high-level meeting of the ‘Cooperation and coordination 
mechanism on drugs’ between the EU and Latin American and Caribbean countries 
in Lima, and took part in the first international meeting of monitoring centres held in 
Caracas in association with 11 national focal points.
With regard to enlargement activities, negotiations between the Commission and 
candidate or third countries for participation in the EMCDDA were followed up and 
support to the Commission provided on an ad hoc basis. The role and activities of the 
EMCDDA were presented to candidate countries and formal relations with candidate or 
third countries having officially applied for membership to the EMCDDA were established.
Activities included follow-up of the evolution of the pre-accession instruments, including 
the programmes supporting the Western Balkans, and the preparation of a technical 
assistance programme on the model developed by Phare. 
The unit also followed up action of the EU towards third countries in fields where a 
contribution of the EMCDDA was expected or in fields that form an integrated part of 
the EU policy on drugs. An information flow between the EMCDDA and the Community 
programmes responsible for implementing the EU policy on drugs in these countries was 
also set up.
General report of activities 2005
32
Following the Decision of the Commission of 3 November 2004 to approve a multi-
beneficiary programme on the participation of Romania and Bulgaria in certain 
Community agencies in 2004 and 2005, the Reitox unit prepared the technical proposal 
(Phare III) for the new project, which started in May for a duration of 18 months with a 
budget of EUR 300,000.
To implement this project, re-assessment missions were organised in Bulgaria and 
Romania, and resulted in a re-assessment report for each country and a work programme 
for 2005–2006. The recommendations made by the EMCDDA were included to a large 
extent in the ‘Comprehensive monitoring report’ presented by the Commission on 25 
October 2005.
The ‘Inception report’ presented by the EMCDDA was approved by the project’s steering 
committee in September 2005. For the first time, the national reports and available 
standard tables and structured questionnaires were delivered by the two countries on 
time, and the information provided will be included in the 2006 Annual report. For the 
first time also, the Annual report was translated into Bulgarian and Romanian, and a 
special event was organised in each country for the national launches of the report, with 
good press coverage in both countries.
The following training activities were organised in 2005:
• Reitox academy workshop on ‘National reporting’ (with the kind support of the Greek 
national focal point) and with the participation of Bulgaria, Romania, Cyprus and Greece 
– Thessaloniki, 27–29 June 2005;
• Reitox national academy on the ‘Early warning system’ – Romania, Bucharest, November 
2005;
• Reitox national academy on ‘Treatment Demand Indicator’ – Romania, Bucharest, 13–14 
December 2005.
On 9 December 2005, the European Commission decided to establish a multi-beneficiary 
programme on the participation of Turkey and Croatia in certain Community agencies, 
including the EMCDDA (Phare IV).
The main objective of the project was to establish and/or strengthen the national focal 
points and national drug information networks in Croatia and Turkey and to integrate 
them further into the Reitox network. The budget earmarked for this activity is EUR 
500,000.
In the perspective of the Communication of the Commission on the participation of 
the Western Balkans in some EU Agencies and at the request of the European Agency 
for Reconstruction, the Reitox unit was invited to participate in a meeting in Serbia-
Montenegro, in the framework of a project organised by the CARDS programme. This 
meeting offered the possibility to obtain a picture of the drugs situation and of the drug-
related data available, as well as to present the work of the EMCDDA.
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Communication and dissemination 
Publications
The objective of the publications programme is to produce both printed and online 
publications addressing the most important aspects of the drugs phenomenon in Europe. 
During 2005, the most significant step forward was to internalise some of the processes 
to do with the Annual reporting package, with a continued emphasis on fine-tuning 
products to fit with the needs of target audiences.
The objectives of the programme included producing a printed publication reflecting the 
main results and achievements of the EMCDDA in 2005; publishing the EMCDDA budget 
in the official EU journal; consolidating and improving the EMCDDA specialised series 
(Monographs, Insights, Manuals and Risk Assessments); and providing a high-quality 
editorial service.
The 2005 Annual report was coordinated, edited and published in 22 languages (all EU 
languages except Maltese plus Norwegian, Bulgarian and Romanian). A concerted effort 
was made to improve the structure and presentation of the Annual reporting package, 
which comprised: the Annual report in 22 languages (printed publication and website); 
the Selected issues (printed publication and website); the Statistical bulletin (PDF and 
website); Country data profiles; Reitox national reports; and a PowerPoint presentation 
summarising the key findings (22 languages). The Statistical bulletin, which provides the 
data sets underlying the report, methodological commentary and notes was produced 
with a new tool facilitating scaleable tables and interactive graphics.
Four editions (49, 50, 51, 52) of Drugnet Europe were published. The first two editions 
were in 5 languages (ES, DE, EN, FR, PT), and then, for budgetary reasons, it was 
decided to produce the newsletter in English only. 
The various EMCDDA websites are increasingly used for the dissemination of studies, 
project reports and summaries and a considerable amount of time was spent on editing 
such material for online dissemination. Online publications included the thematic papers 
on ‘Youth media’ and ‘Illicit drug use in the EU: legislative approaches’. A website with 
drug treatment overviews was published and PERK (Prevention Evaluation Resources Kit). 
Work on further thematic resource areas got underway. (A full list of outputs is provided 
in Annex 3).
Media relations and marketing 
Media relations
EMCDDA media relations activity in the first quarter of 2005 centred around three 
evaluation exercises. These covered: the 2004 Annual report launch; 2004 national 
events coinciding with the Annual report launch; and the newsletter Drugnet Europe. 
Based on responses to questionnaires sent to the national focal points (NFPs) in February, 
three in-depth evaluation reports were drawn up containing practical recommendations 
for implementation throughout the year in these three areas. 
In line with the EMCDDA Media relations strategy, attention was also given at this point 
to developing a press section on the Intranet as a document repository and internal press 
service alerting staff to new press actions and their impact. 
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The focus of the second quarter of the year was a press action for 26 June (International 
day against drug abuse and illicit trafficking) on the youth media, and the conception – 
in cooperation with an external trainer and the Reitox department – of a training module 
for a Reitox Academy on relations with the media. The latter, hosted by the Hungarian 
national focal point in Budapest, allowed an exchange of views on working with the 
media in over 20 countries and offered NFP staff useful guidelines for maximising 
contacts with journalists. The course also took into account the above evaluation reports 
and resulted in further practical recommendations ahead of promotional events in the 
Autumn. 
In the wake of this, NFPs assisted the EMCDDA in drawing up, updating or expanding, 
across 29 countries, contact lists of: top drug-specialised journalists; national press; 
national news agencies and scientific journals.
Efforts in the third quarter focused on the launch of the 2005 Annual report on the state 
of the drugs problem in Europe, held in Brussels on 24 November. Six news releases 
were produced in 22 languages as well as other promotional items and materials. A 
press briefing and conference were held on 23 and 24 November respectively following 
a presentation to the European Parliament. National events were organised, largely 
by the NFPs, in eight EU Member States (Cyprus, Denmark, Estonia, Greece, Finland, 
Lithuania, Poland and Portugal) and in Bulgaria and Romania. These events led to 
unprecedented coverage on the report.
Producing high-quality media relations materials and monitoring impact in the press 
continued to be priorities in 2005. A total of 14 news releases, 6 facts sheets and 10 
press reviews were produced in the course of the year.
In the second half of the year press actions were organised around two VIP visits to the 
EMCDDA: Commissioner for Justice, Freedom and Security Franco Frattini and President 
of the Portuguese Republic Jorge Sampaio. 
Marketing
In the first quarter of 2005, EMCDDA marketing activity focused on the follow-up and 
consolidation of the project ‘Representing the EMCDDA’ following the training course on 
the subject in September 2004. Three reports were finalised: ‘Project development and 
course follow-up’, ‘Minutes/proceedings’, and ‘Staff review’ (written up in final report).
Attention was given at this point to developing a marketing section on the Intranet to 
house these documents and remaining training course materials and to serve as an 
internal service for staff. It provides staff with access to strategic EMCDDA marketing 
documents and new promotional items designed for their use. Among the items 
available are the EMCDDA Marketing strategy; a new repository of marketing items 
(e.g. promotional checklist, PPT presentations, links to brochures etc); ‘Representing the 
EMCDDA’ (full course content and follow-up) and a Corporate Identity section offering 
key items and guidelines.
The range of EMCDDA promotional literature launched with the new corporate identity 
in 2003 was further developed in 2005. This included the publication of a publicity 
brochure on the EMCDDA Monograph series, produced for distribution on the EU 
stand at the Frankfurt Book Fair (October), and an updated brochure EMCDDA Online 
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displayed at the exhibition ‘Online Information 2005’ in London (December) where the 
EMCDDA participated with other EU agencies on the EU stand.  At the end of the year 
a new promotional brochure entered production describing the workings of the May 
2005 ‘Council decision on the information exchange, risk assessment and control of new 
psychoactive substances’.
The joint EU agencies’ brochure, European agencies – working across Europe for you, 
updated at the end of 2004, was printed and disseminated in 23 languages in the 
Spring. The EMCDDA also participated in the annual EU agencies meeting at the EU 
Publications Office (EUR-OP) in July. 
Three promotional mailings were dispatched in 2005 to publicise EMCDDA products to 
book reviewers (scientific press). New products were also promoted via Drugnet Europe 
and the public website.
At the end of the year, at the request of the EMCDDA Management Board, a series of 
graphic banners were designed for use by the Reitox network. These were then integrated 
into a new Corporate identity section on the Reitox extranet along with logos and other 
visual communication tools.
Documentation 
The principal objective of the Library and Documentation Centre is to provide a high 
quality internal information service on drugs and drug addiction covering all EMCDDA 
working areas.
In 2005, the main activities focused on the following areas:
• selection, acquisition, cataloguing, indexing and dissemination of documentary material 
(monographs, journals, specialised articles, reference, newspapers, CD-ROM’s, etc), making 
available useful information in either paper or electronic format to EMCDDA staff; 
• intranet service: electronic dissemination of the journals collection and updating and 
launching of the new software version of Bibliodatabase, the EMCDDA bibliographic 
catalogue, managed by WinLib2000;
• users’ services: circulation of publications, bibliographical retrieval in internal and external 
databases, management of loans, DSI (dissemination of information by profile) and monthly 
publication of the ‘Journals’ table of contents’;
• external users: reply to information and documentation requests thereby offering to 
the target external scientific and professional audiences a reference service on the drug 
phenomenon at European level;
• participation in networking projects and activities with European partners.
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Supporting activities 
Administration
Administrative support
Following the appointment of the new Director in May 2005, a new organisational 
structure for the EMCDDA was adopted which aimed at streamlining and clarifying 
the EMCDDA’s working organisation and the role of the different actors to better 
achieve its objectives. Within this context, the structure of the administrative support 
services (Administration unit) was reorganised and strengthened in order to enhance 
the EMCDDA’s ability to function as a best-practice, knowledge-based and service-
oriented public administration, with special attention paid to the area of human resources 
management.
Planning, evaluation and legal matters
In 2005, work in this area focused on further improving the procedures for budget 
planning and management, with particular attention given to: the operations for 
budgetary transfer and the use of dissociated appropriations; the legal aspects 
concerning the implementation of the reform of the staff regulation; the regulation 
on public access to documents; and the necessary measures taken to cope with the 
inadequacy of the EMCDDA’s current premises. The EMCDDA participated actively in 
the interagency legal network, involving the legal services of the Community regulatory 
agencies.
In February 2005, the Internal audit service of the European Commission conducted an 
audit of the EMCDDA’s internal control system. The audit report was issued in July and 
presented by the Audit manager at the meeting of the Management Board in January 
2006. Some of the recommendations of this report were addressed in the second 
semester of 2005, while other measures are in progress or planned for the coming 
months, as part of an action plan endorsed by the EMCDDA Management Board (see 
Part II below).
Human resources management
Human resource management activities focused on implementing the reform of the EU 
staff regulation that entered into force on 1 May 2004. The EMCDDA participated in the 
activities carried out by all Agencies in cooperation with the European Commission for 
the implementation of the reform.
The internal capacity for human resources management was strengthened and the 
processes for staff recruitment, appraisal and promotion were improved. The recruitment 
procedure for a Head of human resources was only successful second time around. The 
EMCDDA’s capacity in human resources should be enhanced when the appointee takes 
up post.
The selection procedure for the appointment of the new EMCDDA executive Director was 
completed and the newly appointed Director took up his duties on 1 May 2005, for a 
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five-year renewable term. Furthermore, twenty-two selection processes were successfully 
carried out (see Annex 2 for a breakdown by category, grade, nationality and sex of 
staff employed by the EMCDDA at the end of 2005).
Financial management and accounting 
Internal capacity in this area was strengthened and rationalised so as to better cope 
with the increasing workload in terms of procurement operations and to better reflect 
the separation of duties between the accountant and the authorising officer. A first 
implementation of the new rules and procedures for accrual accountancy was carried 
out. Specific measures were taken to improve the processes for financial and contractual 
management and internal control (see Part II below).
Infrastructures and logistics
A new infrastructure and logistics manager was recruited to better manage the current 
premises (split across two sites) and to deal with operations relating to the new EMCDDA 
premises. The contract for renting an EMCDDA ‘bureau de passage’ in Brussels was 
terminated mid-2005. The internal rules for inventory and assets management were 
revised, in accordance with the relevant regulations.
In mid-2005, a steering group was set up for the project relating to the construction 
of new headquarters for the EMCDDA and EMSA (on a plot of land located in Lisbon, 
Cais do Sodré, under the jurisdiction of the Lisbon Port Authority). The remit of the 
steering group is to monitor the construction of the premises and the implementation 
of the memorandum of understanding (MOU) signed in July 2004 with the Portuguese 
Authorities. The group meets every two months at political/management level, and 
at technical level whenever deemed necessary. It is composed of the member of the 
Portuguese Government in charge of the project – currently the Secretary of State 
for National Defence and Maritime Affairs; the Directors of both EU agencies; a 
representative of the Mayor of Lisbon; and the President of the Lisbon Port Authority (APL). 
At the technical level, it is comprised of one permanent representative from each of the 
bodies composing the steering group.
At its first political-level meeting, held on 14 July 2005, the Portuguese Government 
distributed a draft time plan which foresaw the signature of the renting contract between 
the agencies and APL by April 2006 (after the public procurement phase) and the 
inauguration of the headquarters in November 2007, under the Portuguese Presidency. 
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Information technology 
IT infrastructures and services
In 2005, the principal focus of the IT team was on services. Changes were introduced 
in terms of staff roles, work processes and technology, in order to progressively adopt 
market-place best practices in managing electronic services. A services catalogue, service 
desk, incident management, as well as a project management office and security officer 
role are being gradually introduced and defined.
The expansion of the second EMCDDA site continued, requiring the upgrade of the data 
and voice connectivity. This was the subject of a public procurement announced in the 
Official Journal of the European Union, consisting of Internet access, inter-building data 
link, and business continuity components. Three important hardware renewal projects 
were concluded, the first concerning workstations, the second electronic notebooks and 
finally the local area networking switching.
With regard to the extension of some of the services to a mobility context, upgrade 
and consolidations were made to the existing platform for running remote applications, 
opening the possibility to start operating these services from 2006.
Electronic dissemination systems
Multiple projects in this area were driven by the preparations required for the data 
storage and retrieval system project. This project will provide a new information system 
covering the EMCDDA needs in terms of scientific data collection, data validation, and 
the framework for data mining. The procurement was done in the last trimester of the 
year, through an Official Journal competition and concluded with a contract signature. 
This contract will be executed in 2006 and the first semester of 2007.
Another main area of work on aspects of the data storage and retrieval system concerned 
tools for production of online publications. A significant step forward was the in-house 
production of Annual report and related products. For the web content management 
system (CMA) good progress was made in the migration of existing web sites, including 
adaptation to integrate information systems. The system was also upgraded both in 
functional and in technical terms. Although some of the components of this system are 
continuously under development, it was decided that the services to users should also be 
integrated with the ICT service desk, providing a more coherent response to incidents and 
requests.
Adoption of open source software, not only in terms of operating system but also for 
specific application and system needs, has continued to develop as a very promising 
trend. 
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Statutory bodies and executive management 
Management Board 
 
At the 29th meeting of the Management Board in Lisbon on 19–21 January 2005, Mr 
António Maria Costa, Executive Director of the United Nations Office for Drugs and 
Crime (UNODC) in Vienna, addressed the members of the Board to share his views on 
the European drug situation in a global picture, on the eve of the launch of the new 
EU strategy and action plan on drugs. Operational contents of the Memorandum of 
Understanding between UNODC and the EMCDDA will be examined to strengthen the 
collaboration between both organisations.   
The Management Board adopted a budget of EUR 12,515,625 for 2005 (25 Member 
States + Norway), on the basis of an EC subsidy of MEUR 12. It reached a compromise 
on the EMCDDA budget with view to ensuring an EMCDDA annual financing of EUR 
105,000 per Reitox national focal point, without modifying the current 50%-50% 
EMCDDA + Member State co-financing system. Also, the Management Board decided 
to reduce expenditure on statutory meetings and reimbursements of transport costs of its 
members. As a consequence, only one representative per Member State was reimbursed, 
from the July meeting, instead of two. Reimbursements for Scientific Committee members 
and experts were harmonised. 
At the meeting, the Management Board adopted the 2005 work programme and a 
preliminary draft budget for 2006 on the basis of an EC subsidy of EUR 12,360,000.
The Management Board mandated the Director of the EMCDDA to manage the building 
project to house both the EMCDDA and the European Maritime Safety Agency (EMSA) 
in the same location, in close contact with the Bureau, in particular to discuss the terms 
of the contract foreseen in the Memorandum of Understanding with the Portuguese 
Government. The Board mandated the Chair and the Director to sign the contract within 
the budgetary limits endorsed by the Budgetary Authority in September 2004. Also, it 
was decided by two-thirds majority to cease the renting contract of the office in Brussels. 
The Board renewed the mandate of Mr Brunson (BE) and Mr Lawrence (UK) as members 
of the Bureau for 2005. The Management Board bestowed the title of ‘Honorary Director’ 
on Mr Georges Estievenart, whose second term came to an end in December 2004, 
for a decade of service at the EMCDDA’s helm. Mr Jaume Bardolet was appointed as 
acting Director until the new Director was nominated and had taken up his duties. The 
Management Board adopted a revised version of its internal rules of procedure, together 
with an annex on the electoral procedure for the election of the new Director and rules 
for the audition of the candidates.   
In an extraordinary meeting on 19 April 2005, the Management Board elected, by 
two-thirds majority and secret ballot Mr Wolfgang Götz (Germany) as Director of the 
EMCDDA for a renewable five-year term, starting on 1 May 2005. 
Representatives of the acceding countries Bulgaria and Romania, and the acceding 
country Turkey participated, for the first time, as observers in the Management Board 
meeting of 6–7 July 2005. The Management Board had an exchange of views with the 
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new Director, in which he outlined his main priority areas. It decided to discuss the Reitox 
financing from 2007 on at the meeting in January 2006.
Mr Pietsch (AT) and Mr Veresies (CY) were elected members of the Bureau from July 2005 
to July 2006. As they had been members of the Budget Committee, the Board elected 
as their replacements Ms Astrauskiené (LT) and Mr Pérez Pérez (ES) for a three-year 
mandate. Since matters to do with the new premises project would be recurrent, it was 
decided that Portugal would be invited to participate as an observer at Bureau meetings. 
Given that the remit of the Scientific Committee had already been extended twice 
since the end of 2003, and considering that the timing of the recast of the EMCDDA 
founding regulation was difficult to foresee, the Management Board decided to 
dissolve the Scientific Committee and to launch a nomination procedure for a new 
Scientific Committee under the current regulation. The Chairman addressed a letter to 
the permanent representations of the 25 EU Member States and Norway to ask for 
nominations. 
Further to the decision taken in the January meeting, the Board agreed on the structure 
of a questionnaire on the overview of 2005 EMCDDA activities to be completed by its 
members with a ranking between 4 (high priority) and 1 (no priority). The conclusions 
would be discussed in the next Board meeting. 
The Board was informed about the preparations for the presentation and launch of the 
2005 Annual report at the European Parliament in Brussels end of November, and an 
exchange of letters between the Directors of the EMCDDA and WHO/Europe to better 
structure common work areas and profit from synergies. 
The meeting was dedicated to the memory of Mr Willy Brunson (BE) and Mr Armand 
Wagner (LU). Both passed away in the first half of the year.
Bureau  
 
In 2005, the Bureau met four times in Lisbon, and once in Brussels (3). 
At its meeting of 19 January, the Bureau mainly prepared the forthcoming Management 
Board meeting. The Bureau was informed that the EMCDDA was undergoing an internal 
audit by the services of the European Commission, and that the supervisor for the audit of 
European agencies would present the final report of this audit to the Management Board.
On 18 May in Brussels, the new Director outlined his vision and priorities for the Centre. 
The Bureau commented on a first draft agenda for the Management Board meeting of 
July 2005. It further discussed possible options for the Reitox financing as from 2007 on, 
which were forwarded to the Budget Committee. It adopted by written procedure after 
the meeting a proposal for the re-allocation of non-used 2005 Reitox funds mainly for 
Reitox academies, the development of the EMCDDA data storage and retrieval system 
and activities linked to the production of the 2005 Annual report. The Bureau agreed by 
written procedure, after the meeting, to bring forward Management Board meetings from 
January to December to allow for a more timely adoption of the Centre’s annual budget. 
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On 6 July, the Chair of the Budget Committee reported on the meeting held on the same 
day. The Bureau mainly prepared the forthcoming Management Board meeting and 
commented on draft documents.
At its meeting of 13 October, the Bureau was informed about the new organisational 
chart of the Centre. The Bureau commented in general terms on the final report of the 
internal audit, which will be transmitted to the Management Board for its meeting in 
January 2006. The draft agenda for this meeting was revised further to the comments of 
the Bureau, and it was decided that Bureau meetings should take place five to six weeks 
before Management Board meetings, in order to allow discussions on the basis of all 
draft working documents for the Board meeting. The Chair reported on the visit of Vice-
President Frattini of the European Commission to the EMCDDA on 23 September 2005. 
The Bureau further adopted a budget transfer for an amount of EUR 396 000 from Title 1 
to Title 2 mainly for supplementary needs entailed by the execution of the electronic data 
processing tool project to boost the implementation of the EMCDDA information storage 
and retrieval system. On the basis of the proposal of the European Commission to 
advance the July Board meetings to June because of the deadline for the adoption of the 
EMCDDA’s final accounts of the preceding year, the Bureau decided, with the abstention 
of the European Commission, to organise the Management Board meetings from 2006 
on during the first week of July.
Scientific Committee 
Throughout the year, the EMCDDA staff sought advice from the Scientific Committee on 
various occasions. The Scientific Committee was consulted on the draft 2005 Annual 
report and their comments were taken into account as far as possible.
The Committee held its 23rd meeting on 23–24 May 2005. At this meeting, the newly 
elected Director of the EMCDDA, Wolfgang Götz, presented his future ideas for the 
Centre. He emphasised his intention to improve the scientific quality of the Centre’s work 
and to enhance its scientific credibility. In this context, the Scientific Committee would be 
a valuable resource to be better activated. The Scientific Committee welcomed the key 
concepts and concrete elements outlined by the Director and assured their full support.
The Committee reflected on the achievements of the Scientific Committee during its 
mandate and discussed its role for the future. The usefulness of small, specific sub-
groupings was pointed out. Scientific support should be flexible and dependent on the 
particular needs of the EMCDDA. 
While awaiting the recast of the EMCDDA Regulation, the term of the Scientific 
Committee had been extended twice since 2003. The EMCDDA Management Board 
therefore decided at its meeting on 6–8 July 2005 to launch a procedure under 
the provisions of Council Regulation (EEC) No 302/93 for the nomination of one 
representative from each Member State and Norway to serve on the Scientific Committee 
for a three-year period. 
By early November, unfortunately, only about half of the Member States had nominated 
Scientific Committee members. It was decided to postpone the originally planned 
November meeting and to proceed with a written procedure for the formal opinion of 
the Scientific Committee (in this case of the nominated members) on the 2006 EMCDDA 
work programme. The Chairperson of the Scientific Committee drafted an opinion with 
the assistance of EMCDDA staff; it was adopted and presented to the Management Board 
in January 2006.
In its opinion, the Scientific Committee voiced its confidence that the restructuring of 
the scientific programmes and the construction of a formal scientific coordination would 
facilitate a cross-sectional, multidimensional scientific analysis of the drugs phenomenon. 
It pointed out that for such efforts to be sustained, however, sufficient resources in 
terms of human capacity and time must be assured. The Committee welcomed the 
continuous work on the five key epidemiological indicators, appreciating the progress 
made in streamlining data collection. Regarding the implementation of Council Decision 
20005/387/JHA on the information exchange, risk-assessment and control of new 
psychoactive substances, the Committee committed itself to taking a leading role in the 
revision of the risk-assessment guidelines. The Scientific Committee supported the attention 
given to the identification and dissemination of best practice in the work plan. In relation 
to the new EU drugs action plan (2005–2008) it pointed out that the analysis of the 
impact of the plan should fully utilise the data available to the EMCDDA, with respect for 
appropriate scientific and statistical procedures. 
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Characteristics and nature of the EMCDDA 
management and internal control systems 
The EMCDDA has set up its internal procedures for budget execution and internal control 
in accordance with the financial regulation applicable, which transposes integrally the 
text of the Framework financial regulation nº2343/2002. A partially decentralised 
management model has also been defined and implemented. 
As a consequence, both operational and financial decisions required for implementing 
the work programme and budget have been decentralised by delegation to the Heads of 
unit on which the EMCDDA’s activities and working organisation relies. 
The Administrative unit provides the support to operational managers for financial 
management and ensures internal planning and monitoring, as well as the ex ante 
verification of transactions. 
These procedures have been codified and all Heads of unit/deputy authorised officers 
have received a specific training and information on their role duties and liability, in 
accordance with the relevant provisions of the financial and staff regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be 
summarised as follows:
• Project manager – initiative and operational input for the administrative and financial 
operations required to implement projects (technical specifications for tendering procedures, 
cost estimate, ‘certified correct’ for payments). 
• Financial management team – financial helpdesk: preparation of the required 
administrative and contracting supporting documents with the input of the concerned project 
manager.
• Planning and evaluation team – checking of compliance with adopted work programme 
and budget.
• Financial management team – SI2 initiating officers: operations in the EMCDDA SI2 
electronic management and accounting system to prepare the decision of the authorising 
officer. 
• Financial management team – verifying officer: ex ante verification. 
• Head of unit – authorisation of the required budgetary and legal operations, acting as 
deputy authorising officer for the execution of the programme concerned.
• Accountant – execution of the required financial transactions.
The above-mentioned procedures are consistent with the EMCDDA project-based working 
methods aimed at integrating activities and resources management, in accordance with 
the activity-based management and budgeting (ABM/ABB) principles. 
In this context, the Centre has established procedures for planning, monitoring and 
reporting, with a clear indication of the actors involved, their role and responsibilities.
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Following the adoption by the EMCDDA Management Board, in January 2003, of the 
new ‘Operating framework for the Reitox system’ a new grant agreement model was 
introduced for the annual co-financing of the activities of the Reitox national focal points, 
which fully complies with the relevant provisions of new financial regulation applicable to 
the EMCDDA. This agreement requires that an external annual audit has to be carried out 
by an independent body or expert officially authorised to carry out audits of accounts in 
order to certify that the financial documents submitted to the EMCDDA by the beneficiary 
comply with the financial provisions of the agreement, that the costs declared are the 
actual costs, and that all receipts have been declared. 
The European Court of Auditors and the European Anti-Fraud Office (OLAF) enjoy the 
right of access for the purposes of checks and audits.
Taking into account the current dimension of the EMCDDA activity and structure and 
considering the budgetary constraints, the EMCDDA has not set up its own internal audit 
capability, relying for this function on the Commission’s Internal Auditor, in accordance 
with the applicable financial regulation. A post for this purpose has been foreseen in the 
EMCDDA preliminary draft budget for 2007.
Key features of the EMCDDA’s partially decentralised management model
Actors/level of operations Role/operations
Decentralised level (operational and 
technical units)
Operational initiative/input and 
operational and financial decisions by 
delegation in order to implement the work 
programme (WP) and budget
Central level (Directorate and 
administrative units)
Coordination and management of 
executive planning, monitoring, reporting 
and assessment of the implementation of 
the WP and budget
Administrative and financial 
support, management and control of 
implementation
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Key features of the process for the execution of the EMCDDA work programme and 
budget
Level of operations Actors Role/operations
Decentralised level 
(operational and technical 
units)
Concerned project manager 
and Head of unit
Initiative and operational 
input for the operations 
required to implement 
projects
Central level (administrative 
unit)
Planning and evaluation 
team
Check compliance of 
operations with adopted 
WP and budget plan. 
Budgetary appropriations 
to be committed are set 
aside
Human resources 
management team
Define rights and check 
compliance with staff 
regulations for missions and 
staff-related expenditure
Financial management 
team
Prepare the required 
administrative and legal 
supporting documents and 
control compliance with 
applicable regulations. 
Process and control the 
required SI2 operations
Decentralised level 
(operational and technical 
units)
Head of unit/deputy 
authorising officer
Authorise budgetary and 
legal commitments and 
payments (and recovery 
orders)
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Assessment and improvement of management and 
internal control systems 
Follow-up to the recommendations by the European Court of Auditors and discharge 
Authority following the audit concerning the financial year 2004
The following measures have been taken by the EMCDDA in order to improve its 
management and internal control systems, providing follow-up to the observations and 
recommendations expressed by of the European Court of Auditors and the discharge 
Authority:
• Substantial reduction (around 50%) of the budgetary transfers.
• Better planning of procurements operation.
• Specific training for EMCDDA managers (deputy authorising officers and initiating 
officers) on tendering and contracting procedures.
• Standardisation of contract procedures and tools.
• Better definition of the internal procedures for commitment.
• Introduction of checklists for payments and other budgetary operations.
• Monthly reconciliation procedure between bank balances and accounts.
• Strengthening of the working capacity for procurement/contract technical support 
and management (new recruitments for financial helpdesk, strengthening and better 
organisation of ICT and infrastructure/logistics management).
• Concerning assets management, the closure of the 2005 inventory has been based on a 
new electronic inventory system.
Follow-up to recommendations by the Internal Audit Service of the European 
Commission (IAS) following the audit of the EMCDDA internal control system carried out 
in 2005
Between November 2004 and early February 2005, the IAS carried out an audit of the 
EMCDDA internal control system. The resulting audit report was issued on 15 July 2005 
and was presented by the audit manager at the meeting of the EMCDDA Management 
Board of January 2006. 
The new EMCDDA Director took up his duties in May 2005, presenting as one of his 
aims the achievement of the highest level of management efficiency for the EMCDDA, 
introducing change while guaranteeing continuity and stability, providing leadership 
and applying good management practice. As a consequence some of the core 
shortcomings highlighted in the audit report were addressed in the second semester of 
2005. The measures taken can be summarised as follows:
• Adoption of a new organisational chart clearly defining duties and responsibilities 
while rationalising working organisation in accordance with EMCDDA objectives. The 
new structure has streamlined and clarified the EMCDDA’s working organisation, both 
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with regard to the mission and to the role of the different actors. In this context, the 
Scientific Coordination will play a leading role with regard to strategic planning and 
coordination of EMCDDA core activities and the merging of the scientific programmes 
should allow for better teamwork, better understanding of roles and better use of 
resources. Furthermore the reorganised structure and activities aimed at supporting 
EMCDDA operations should enhance the ability of the EMCDDA to function as a best-
practice, knowledge-based and service-oriented public administration. 
• With regard to human resources management, measures were taken to improve job 
descriptions, recruitment and staff appraisal and promotion processes, in accordance 
with specific recommendations expressed by the IAS. The recruitment of a human 
resources manager should enhance the EMCDDA’s capacity in this area.
• As regards compliance and regularity, action was taken to improve the delegation 
of powers of the EMCDDA authorising officer, the procedures for public procurements 
and the segregation of roles and duties in financial processes, the definition of a 
countersigning system for bank transactions as well as the implementation of procedures 
to document exceptions.
Other measures are in progress or planned for the forthcoming months, as part of an 
action plan endorsed by the EMCDDA Management Board at its meeting of January 
2006, aimed at following up the recommendations of the above-mentioned IAS internal 
audit report within the framework of a more comprehensive strategy aimed at improving 
the EMCDDA’s management and internal control systems. 
Priority will be given to addressing the ‘critical’ and ’very important’ IAS 
recommendations, mostly relating to improving the control environment and particularly 
improving human resources management, at the same time recognising that the areas 
interrelate and some less urgent areas may also benefit as a spin-off of corrective 
measures implemented for the ‘critical’ and ‘very important’ issues. 
These measures can be summarised as follows:
• Preparation and adoption of EMCDDA rules for the implementation of the revised EC staff 
regulations on temporary posting (interim) for management functions;
• Completion of the revision of job descriptions for EMCDDA posts, in accordance with the 
new organisational chart;
• Setting up and implementation of procedure for assigning objectives for staff appraisals; 
• Inventory of EMCDDA sensitive posts/functions;
• Streamlining of current EMCDDA reporting system/procedures and strengthening the 
capacity for reporting and monitoring the execution of the EMCDDA work programme and 
budget; 
• Developing a specific capacity for risk assessment and internal audit; 
• Developing ex post verifications.
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Declaration of assurance of the authorising officer
I, the undersigned, Director of the European Monitoring Centre on Drugs and Drugs 
Addiction,
in my capacity as authorising officer: 
• declare that the information contained in this report gives a true and fair view (*).
• state that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance 
with the principles of sound financial management, and that the control procedures put 
in place give the necessary guarantees concerning the legality and regularity of the 
underlying transactions.
This reasonable assurance is based on my own judgment and on the information 
at my disposal, such as the results of the self-assessment, ex post controls, the 
observations of the Internal Audit Service and the lessons learnt from the reports of 
the Court of Auditors for years prior to the year of this declaration.
• confirm that I am not aware of anything not reported here which could harm the 
interests of the Agency and the institutions in general.
Done in Lisbon, on 7 July 2006
 
Wolfgang Götz
Director
57
Chapter 3 
(*) True and fair in this context means a reliable, complete and correct view on the state of affairs in 
the service.
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Annex 2 
Breakdown of EMCDDA staff in 2005
EMCDDA officials and temporary staff
Category and grade
 
Nationality
 
Sex Total by
category and gradeFemale Male
A* 16  0 0  
A* 15  0 0  
A* 14     
Temporary agents DE 0 1  
    1
A* 13  0 0  
A* 12     
Temporary agents SE 1 0  
 NO 0 1  
 PT 0 1  
 FR 0 1  
 UK 0 1  
 5
A* 11     
Officials BE 1 0  
 ES 0 1  
 IT 0 1  
Temporary agents DE 0 1  
 UK 1 0  
 NL 0 1  
 BE 0 1  
    7
A* 10  
Temporary agents PT 1 1  
61
Annexes
Category and grade
 
Nationality
 
Sex Total by
category and grade
Female Male
 ES 1 1  
 FR 1 0  
 UK 2 1  
 IT 0 1  
 9
A*  9     
Officials  
Temporary agents IT 1 0  
 DE 0 1  
 2
A*  8     
Officials  
Temporary agents DE 2 0  
 FR 1 0  
 IE 0 1  
 DK 0 1  
    5
A*  7     
Temporary agents 0 0  
    0
A*  6     
Temporary agents BG 0 1  
 DE 1 0  
 SK 1 0  
    3
A* 5     
 0 0  
Total  A 14 18 32
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Category and grade
 
Nationality
 
Sex Total by
category and grade
Female Male
B* 11  0 0  
B* 10     
Officials PT 1 0  
Temporary agents 0 0  
    1
B* 9  0 0  
B*  8     
Officials  
Temporary agents DE 1 0  
  
    1
B* 7     
Officials BE 0 1  
Temporary agents FR 2 0  
 BE 0 1  
 ES 1 0  
    5
B* 6     
Officials  
Temporary agents BE 0 1  
 PT 0 1  
    2
B* 5     
Temporary agents IT 0 1  
 GR 1 0  
    2
B* 4     
Temporary agents BE 1 0  
    1
B* 3     
Temporary agents BE 1 0  
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Category and grade
 
Nationality
 
Sex Total by
category and grade
Female Male
 PT 0 1  
 FR 0 1  
 UK 0 1  
    4
Total B 8 8 16
C* 7  0 0  
C* 6     
Temporary agents PT 1 0  
 GR 1 0  
    2
C* 5     
Temporary agents PT 1 0  
    1
C* 4     
Temporary agents PT 1 0  
 1
C* 3     
Temporary agents PT 1 0  
 LU 0 1  
    2
C* 2  
Officials PT 1 0  
Temporary agents PT 1 0  
    2
C* 1     
Temporary agents PL 1 0  
    1
Total C 8 1 9
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Auxiliary staff 
Category and grade
 
Nationality
 
Sex
Total by
category and gradeFemale Male
A II  0 0  
A III LU 0 1  
    1
Total Auxiliary agents 0 1 1
Contractual staff 
Category and grade
 
Nationality
 
Sex
Total by
category and grade
Female Male
GF I     
 PT 0 2  
    2
GF II     
 PT 6 1  
  
    7
GF III     
 PT 1 1  
 DE 1 0  
 IT 0 1  
    4
GF IV UK 1 0  
  
    1
Total Contract agents 9 5 14
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Annex 3 
Outputs
Publications
Annual report 2005: the state of the drugs problem in Europe
A yearly overview of the drug phenomenon in Europe.
Available in 22 languages – all EU official languages (except Maltese), Bulgarian, 
Norwegian and Romanian.
Cat. No.: TD-AC-05-001-BG/CS/DA/DE/EN/ES/ET/FI/FR/GR/HU/IT/LT/LV/NL/NO/PL/
PT/RO/SK/SL/SV-C
http://www.emcdda.europa.eu/?nnodeid=419 
Also available as a 22-language website with additional explanatory material, graphics and 
data sources (http://ar2005.emcdda.europa.eu) 
Annual report 2005: selected issues
Three in-depth reviews that accompany the report: Drug-related public nuisance, Alternatives 
to imprisonment, Buprenorphine
Available in EN.
Cat. No.: TD-AF-05-001-EN-C
Also available as a website (http://issues05.emcdda.europa.eu) 
Statistical bulletin 2005
The full set of source tables on which the statistical analysis in the Annual report is based 
and details on the methodology used.
Available in EN.
ISBN 92-9168-245-4
Also available as a website (http:stats05.emcdda.europa.eu)
General report of activities 2004
A detailed progress report of the EMCDDA’s activities over a 12-month period.
Available in EN.
(http://www.emcdda.europa.eu/?nnodeid=426)
Drugnet Europe 
The EMCDDA’s newsletter, provides regular, rapid and succinct information on the Centre’s 
activities to a broad readership.
4 editions (49, 50, 51, 52) 
49 and 50 available in ES/EN/DE/FR/PT. 51 and 52 in EN only. 
http://www.emcdda.europa.eu/?nnodeid=411
 
Technical data sheets
Differences in patterns of drug use between women and men
Thematic papers
Illicit drug use in the EU: legislative approaches
Youth media
General report of activities 2005
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Marketing materials 
‘EMCDDA Monographs’ catalogue
In this catalogue, the EMCDDA showcases its series of scientific monographs which offer 
expert opinion and comprehensive research from leading drug specialists in the EU and 
other world regions.
Available in EN.
http://www.emcdda.eu.int/?nnodeid=12844
‘EMCDDA online’ promotional brochure
This brochure publicises the EMCDDA’s latest online products.  
Available in EN.
http://www.emcdda.eu.int/?nnodeid=6041 
Joint agencies’ brochure European agencies – working across Europe for you 
Available in 23 languages.
http://www.emcdda.eu.int/?nnodeid=438
Media products 
News releases 
14 news releases (totalling 94 products). 
No 1 – Overdose: a major cause of avoidable death among young people 
(12.1.2005 ) EN/FR/PT
No 2 – Co-morbidity: drug use and mental disorders 
(12.1.2005) EN
No 3 – Male and female drug use: Is the gap narrowing? 
(8.3.2005) EN
No 4 - Upcoming changes at EU drugs agency 
EMCDDA Management Board chooses new Director
(19.4.2005) DE/EN/FR/PT
No 5 - WHO and EMCDDA join forces 
Better guidance for treating HIV/AIDS and hepatitis among injecting drug users
(16.6.2005) EN
No 6 - 26 June: International day against drugs 
Youth media uncover emerging drug trends among young people 
(23.6.2005) 
EN/FR/PT
No 7 – Vice-President of the European Commission at EMCDDA 
Agency offers vital tools for informing drug policy, says Frattini
(23.9.2005) DE/EN/FR/IT/PT
No 8 – Latest on the drug problem across Europe 
2005 Annual report  from the EU drugs agency
ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/BG/RO/
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No 9 – Annual report 2005: Cocaine, amphetamines, ecstasy and cannabis: latest trends 
(24.11.2005) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/
BG/RO 
No 10 – Annual report 2005: Infectious diseases, problem drug use and drug-related deaths
Heterosexual transmission overtakes injecting drug use as route of new AIDS cases 
(24.11.2005) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/
BG/RO 
No 11 – Annual report 2005: Over half a million Europeans now receive substitution 
treatment
Major increase in services for opiate dependence, but availability still uneven
(24.11.2005) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/
BG/RO 
No 12 – Annual report 2005: New developments in drug policy and law 
Growing concern over impact of drug use on our communities 
(24.11.2005 ) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/
BG/RO 
No 13 – Annual report 2005: Focus on crime and prison
Most EU countries report increases in drug law offences
(24.11.2005) ES/CS/DA/DE/ET/EL/EN/FR/IT/LV/LT/HU/NL/PL/PT/SK/SL/FI/SV/NO/
BG/RO 
2005 Annual report information package 
A list of products and services 
EN
No 14 – Portuguese Head of state visits EMCDDA 
President expresses confidence in Portuguese response to drugs 
(21.12.2005) EN/PT 
Fact sheets 
6 Fact sheets (EN). 
Fact sheet 1: Illicit drug use in the EU: legislative approaches
Fact sheet 2: EU drugs agency welcomes 500th EDDRA entry
Fact sheet 3: Profile – Wolfgang Götz
Fact sheet 4: New legal instrument on psychoactive substances
Fact sheet 5: Joint agreement signed in Lisbon
Fact sheet 6: Reitox training academy on selective prevention
 
http://www.emcdda.europa.eu/?nnodeid=16965 
Press reviews
4 quarterly press reviews
5 ad hoc press reviews (International day against drug abuse and illicit trafficking, Visit by 
EMCDDA Director to Slovakia, Visit by EMCDDA Chairman and Director to the Baltic States, 
Visit to EMCDDA by Vice-President Frattini, Visit to EMCDDA by President Jorge Sampaio)
1 three-volume 800-page Annual report press review
General report of activities 2005
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Websites 
EMCDDA public website
The gateway to drug information in Europe. Ongoing updates and content development.
http://www.emcdda.europa.eu 
Annual report 2005
The multilingual Annual report website offers full online version of the report in 22 languages 
and press materials.
http://ar2005.emcdda.europa.eu
Statistical bulletin 2005
The bulletin is a companion publication to the EMCDDA Annual report and presents the full 
set of source tables on which the statistical analysis in the annual report is based. It also 
provides further detail on the methodology used and over 100 additional statistical graphs.
http://stats05.emcdda.europa.eu
Country situation summaries
Country situation summaries are available for 25 Member States and Norway. They offer a 
rich pool of national drug data in Europe. Their main purpose is to provide brief synopses 
of up-to-date national data and trends. They also include selected links to other national 
information sources. They are updated once a year.
http://profiles.emcdda.europa.eu/?nnodeid=1966
Drug treatment overviews
The ‘Drug treatment overviews’ describe the national drug treatment systems operating in the 
25 EU Member States, Bulgaria, Romania and Norway.
http://www.emcdda.europa.eu/?nnodeid=7613
European legal database on drugs
The European legal database on drugs (ELDD) is the EMCDDA’s online database of 
information on European drugs-related legislation for the EU Member States and Norway. 
Ongoing updates and content development.
http://eldd.emcdda.europa.eu
Evaluation instruments bank
The EMCDDA’s Evaluation instruments bank (EIB) is a document archive of tools created 
to encourage evaluation using reliable methods, and to help to standardise these tools at 
European level. The Instruments Bank contains tools for evaluating both prevention and 
treatment programmes. Ongoing updates and content development.
http://eib.emcdda.europa.eu
Exchange on drug demand reduction action
The Exchange on drug demand reduction action (EDDRA) is a multilingual online information 
system and data-collection tool on best practice in responding to drug use in the European 
Union. Ongoing updates and content development.
http://www.emcdda.europa.eu/?nnodeid=1580
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Technical reports 
Donmall, M., (2005) ‘Global toolkit on drug treatment demand’, Report CT.04.P1.286, 
EMCDDA, Lisbon.
Europol-EMCDDA Joint report on new psychoactive substance 1-(3-chlorophenyl)piperazine 
(mCPP). Report submitted to the Council, the Commission and the EMEA.
Kontogeorgiou, K., Wiessing, L., et al. (2005) ‘Protocol for the implementation of the 
EMCDDA key indicator drug-related infectious diseases (DRID)’, Report CT.04.P1.337, 
EMCDDA, Lisbon.
Merino, P. P. (2005) ‘Inventory of health and social measures targeting drug users in prisons 
in the EU (15 + 1)’, EMCDDA, Lisbon.
Merino, P. P. (2005) ‘Inventory of health and social measures targeting drug users in prisons 
in recently incorporated EU Member States’, EMCDDA, Lisbon.
Olszewski, D., Seppala, P., Fotiou, A., Pike, B., Leibrand, S., Feijao, F. ‘Youth media’, 
Lisbon, EMCDDA 2005.
Royuela Morales, L., ‘Assistance to the EMCDDA for detailed data collection in the new 
Member States and candidate countries on drug-related deaths following the EMCDDA 
standard protocol for ‘drug-related deaths’, Report CT.04.P1.359, EMCDDA, Lisbon.
Stockholm University, (2005) ‘Regular and intensive use of cannabis: problems and 
responses’, Report CT.04.P1.371, EMCDDA, Lisbon.
Vicente, J., Cruts, G., Van Laar, M., et al. (2005) Revised drug-related death standard 
protocol, version 3.1. EMCDDA, Lisbon. Revision and update of Report CT.02.P1.05  (The 
DRD standard protocol, version 3.0).
Articles and abstracts
Articles in peer-reviewed journals
Bargagli, A. M., Hickman, M., Davoli, M., Perucci, C. A., Schifano, P., Buster, M., Brugal, 
T., Vicente, J., ‘Drug-related mortality and its impact on adult mortality in eight European 
countries’. The European Journal of Public Health Advance Access, 2005.
King, L. A., Carpentier, C., Griffiths, P., ‘Cannabis potency in Europe’. Addiction, 100, 884-
886.
King, L. A., Carpentier, C., Griffiths, P., ‘Getting the facts right: a reply to Smith (2005)’. 
Addiction, 100, 1560-1561.
Reimer, J., Schulte, B., Castells, X., Schafer, I., Polywka, S., Hedrich, D., Wiessing, L., 
Haasen, C., Backmund, M., Krausz, M. ‘Guidelines for the treatment of hepatitis C virus 
infection in injection drug users: status quo in the European Union countries. Clin Infect Dis 
2005;40 Suppl 5:S373-8.
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Smit, F., van Laar, M., Wiessing, L. ‘Estimating problem drug use prevalence at national 
level: comparison of three methods’. Drugs: education policy and prevention (In press).
Vicente, J., Hedrich, D., ‘Sobredosis: una causa de muerte evitable’. Centro de 
Documentación de drogodependencias, 2005.
Wiessing, L., ‘European drugs agency highlights trends in drug use and problems affecting 
drug users’. Eurosurveillance 2005;10 (12): 051215 http://www.eurosurveillance.org/
ew/2005/051215.asp#3
Book chapters and other articles
Taylor, C., Griffiths, P., ‘Sampling issues in drug epidemiology’. Epidemiology of drug 
abuse, 2005; chapter 6, pp 79-98.
Hickman, M., Taylor, C., ‘Indirect methods to estimate prevalence’. Epidemiology of drug 
abuse, 2005; chapter 8, pp 113-131.
Griffiths, P., McKetin, R., ‘A common language for a common problem: the developing role 
of drug epidemiology in a global context’. Epidemiology of drug abuse, 2005;  chapter 11, 
pp 161-176.
Montanari, L., ‘I pazienti in trattamento per uso di droga in Europa’ in Malagoli, M., 
Cooperazione sociale e inserimenti lavorativi, ITACA, n.12.
Montanari, L., Taylor, C., Griffiths, P., Vicente, J., ‘Gender breakdown among clients starting 
treatment in outpatient treatment centres in nine European countries in 2002, in Kraus, L., 
Korf, D. J., Research on drugs and drug policy from a European perspective, Pabst Science 
Publisher, 2005.
Montanari, L., (2005), ‘Spunti  introduttivi e osservazioni conclusive’, Ugolini, P. (2005), 
Qualità e outcome nelle dipendenze, F. Angeli, Milano.
Published abstracts and oral presentations at scientific conferences and meetings
Griffiths, P., ‘Overview of European drug situation’. Community Epidemiology Work Group. 
Denver, USA, 14–17 June, 2005.
Griffiths, P., ‘HIV and drug use in Europe’. 2005 NIDA International Forum Linking Drug 
Abuse and HIV/AIDS Research. Orlando, USA, 17–20 June, 2005.
Griffiths, P., ‘Monitoring drug use in Europe’. Meeting of EU and LAC Drugs Observatories. 
Caracas, Venezuela, 28–30 November 2005.
Montanari, L., ‘Profile of drug clients in Europe and recent trends’, Romania.
Montanari, L. ‘Treatment demand indicator: a breakdown by gender in some European 
countries’, CLAT, Barcelona, 30 June 2005.
Montanari, L., ‘Recent trends among population treated for drug use in Europe’, Coimbra, 
3TE, 24 June 2005.
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Montanari, L., ‘Data availability and quality of treatment demand data (TDI) in low-threshold 
agencies, Lisbon, EMCDDA, expert meeting 1–2 June 2005.
Montanari L., Recent trends in drug use and problematic drug use in Europe, Ecole National 
de la Santé Publique, 28 September 2005
Montanari L., Trends among opiates clients entering drug treatment. Results from the 
Treatment Demand Indicator, Lisbon, EMCDDA, Annual Expert Meeting on Problem Drug 
Use, 20 October 2005
Montanari, L., Felgueiras G., ‘Social exclusion and drug use’, 15–16 November 2005.
XV Congresso sobre ‘Estilos de vida e comportamentos aditivos’.
Nilson, M., ECCAS (European Collaborating Centres in Addiction Studies) Monograph No. 
4, Comorbidity: European responses to comorbidity (in press).
Olszewski, D., Gender analysis group ESPAD. The European school survey project on 
alcohol and other drugs, 2005 project meeting, Faroe Islands, September 12–13, 2005.
Olszewski, D., ‘Report on the state of the drugs problem in Europe’, Ministry of Health, 
Warsaw, Poland, 25 November 2005.
Olszewski, D., ‘New synthetic drugs in Europe and the challenge of monitoring new 
psychoactive substances’. London Toxicology Group, LTG Meeting London, 14 October 
2005.
Olszewski, D., ‘Differences in patterns of drug use between women and men’, Seminário 
homens e mulheres em Portugal, Instituto Nacional de Estatistica, 23 November 2005.
Vicente, J., ‘Epidemiological situation on drug-related deaths’. Reitox Academy Intensive 
Course: Harm reduction data and reporting. Lisbon, EMCDDA, 26–27 September 2005.
Vicente, J., Hedrich, D., Griffiths, P. ‘Drug-related deaths and responses in the EU.  16th 
International Conference on the Reduction of Drug Related Harm. 20-24 March 2005, 
Belfast, UK (abstract)
Vicente, J., ‘Overview of the key Indicator: progress, limitations and perspectives. Overview 
of 2005 results on population surveys. EU expert meeting on Prevalence of drug use among 
the general population, Lisbon, EMCDDA, 27–28 June 2005.
Vicente, J., ‘Assessment of intensive patterns of drug use through population surveys: 
rationale. EU expert meeting on Prevalence of drug use among the general population, 
Lisbon, EMCDDA, 27–28 June 2005.
Vicente, J., Beck, F. and Legleye, S. ‘Presentation of a questionnaire to identify work in 
national surveys to measure intensive forms of drug use’, EU expert meeting on Prevalence 
of drug use among the general population, Lisbon, EMCDDA, 27–28 June 2005.
Vicente, J. ‘Review of progress on the key Indicator and findings for the year 2005’, EU 
expert meeting on Drug-related deaths and mortality among drug users, Lisbon, EMCDDA, 
24–25 November 2005.
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Vicente, J. and Matias, J. ‘First exploration of DRD data and drug mortality in different 
EU countries’, EU expert meeting on Drug-related deaths and mortality among drug users, 
Lisbon, EMCDDA, 24–25 November 2005.
Vicente, J. ‘Improvement of basic information on substances involved in acute DRD and 
proposal for a field trial. EU expert meeting on Drug-related deaths and mortality among 
drug users, Lisbon, EMCDDA, 24–25 November 2005.
Wiessing, L., ‘Short update on the EMCDDA key indicator ‘Drug-related infectious diseases’. 
Expert meeting on data collection at low-threshold agencies: ‘increasing availability and 
quality of information at European level’. Lisbon, EMCDDA, 2–3 June 2005.
Wiessing, L., Taylor, C., ‘Some comments on measuring problem drug use. Indicator 
prevalence of drug use among general population’, annual expert meeting. Lisbon, 
EMCDDA, 27–28 June 2005.
Wiessing, L., ‘Developing a more detailed protocol for the drug-related infectious diseases 
indicator’, Treatment demand indicator (TDI) 2005 annual expert meeting. Lisbon, EMCDDA, 
22–23 September 2005.
Wiessing, L., ‘Considerations on monitoring coverage. Reitox Academy intensive course: 
Harm reduction data and reporting. Lisbon, EMCDDA, 26–27 September 2005.
Wiessing, L., ‘EMCDDA key indicator drug-related infectious diseases: activities, needs and 
plans’. EU expert meeting on drug-related infectious diseases. Lisbon, EMCDDA, 18–19 
October 2005.
Wiessing, L., ‘EMCDDA key indicator problem drug use: activities, needs and plans’. Expert 
meeting on problem drug use, Lisbon, EMCDDA, 20–21 October 2005.
Wiessing, L., Reitox Academy training on the EMCDDA key indicator drug-related infectious 
diseases (DRID). Malta, 14–15 December 2005.
Klavs, I., Wiessing, L., ‘Drug-related infectious diseases and risk behaviour in the EU. 16th 
International conference on the reduction of drug-related harm. 20–24 March 2005, Belfast, 
UK (abstract).
Aceijas, C., Hickman, M., Sarang, A., Bykov, R., Wiessing, L., and Hedrich, D. ‘Coverage 
of needle and syringe programs in developing and transitional countries’. 16th International 
conference on the reduction of drug-related harm. 20–24 March 2005, Belfast, UK 
(abstract).
73
Annexes 
Participation in conferences and meetings, and technical meetings organised 
Date Venue Title Participants
Director
3–4 May Brussels Meeting with Vice-President Frattini's Cabinet and 
with DG JLS
Policy makers
11–13 May Brussels Horizontal Drugs Group and meeting with DG JLS Policy makers
17–18 May Brussels Bureau meeting and meeting in the European 
Parliament
Policy makers
8–9 June Strasbourg Meeting in the European Parliament and official 
closure of the Luxembourgish Presidency
Policy makers
16 June Brussels Heads of Agencies meeting Policy makers
20 June Brussels Horizontal Drugs Group Policy makers
21 June Brussels Meetings in DG JLS and DG ADMIN Policy makers
28 June London Conference organised by the Home Office 'Crime 
reduction and community safety group'
Policy makers
11 July Strasbourg 2nd French-German conference on addictions, 'Le 
cannabis en 2005. Quelles politiques publiques?'
Policy makers, 
practitioners
13–14 Septemebr Brussels Meeting in the European Parliament with DG JLS Policy makers
29–30 September Bratislava Visit to Slovakian drug authorities Policy makers
13–14 October Brussels Meetings in the European Parliament with DG JLS Policy makers
24 October Brussels Horizontal Drugs Group Policy makers
25–26 October Budapest 48th International ICCA Conference on 
Dependencies
Scientists
9 November Brussels DG JLS, EMCDDA Budget Committee meeting Policy makers
14 November Berlin Deutsche Hauptstelle für Suchtfragen, 
Fachkonferenz Sucht 2005
Practitioners
22–24 November Brussels Annual report launch Policy makers, 
media
25 November Porto National launch of the Annual report in Portugal Policy makers
1–2 November Toledo Seminar: 'The national plan on drugs in the 
international context'
Policy makers
4–6 December Palermo 4th national conference 'Sui problemi connessi alla 
diffusione delle sostanze stupefacenti e psicotrope'
Policy makers
7 December Brussels EU Drugs Coordinators meeting Policy makers
12–16 December Vilnius, Riga, 
Tallin
Visit to Lithuania, Latvia and Estonia Policy makers
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Programme 1 – Monitoring the drugs situation – General 
7–9 March Vienna Forty-eighth session of the Commission on Narcotic 
Drugs
Policy makers
21 April Brussels Meeting on EU drugs action plan (2005–2008) Policy makers 
11–12 May Cagliari International network to improve management in 
Europe
Experts
14–17 June Denver Community Epidemiology Work Group (CEWC) Experts
17–20 June Orlando 2005 NIDA International Forum Linking Drug 
Abuse and HIV/AIDS Research
Experts
23–25 June Coimbra Conference ‘Models of European responses 
to multiple forms of abuse of psychoactive 
substances/Drug perspectives at the beginning of 
the Century’
Experts
30 June–2 July Barcelona CLAT 3 2005, 3rd conference on reduction of 
drug-related harms
Experts
14 July Brussels Horizontal Drugs Group Policy makers 
8–9 August Krakow Workshop on quantitative analysis of drug data Experts
27–28 September Vilnius International forum ‘Drug control in Baltic regions: 
new challenges’
Policy makers 
14 October London New synthetic drugs in Europe and the challenge 
of monitoring new psychoactive substances,  
London Toxicology Group
Experts
27–29 October Manchester 16th annual conference of the European Society 
for Social Drug Research (ESDD)
Network 
members
31 October–2 
November
Vienna Expert workshop on measuring progress in 
demand reduction
Experts
4–5 November Sesimbra CEOS meeting on ‘Hidden behaviours’ Experts
9–10 November Paris Pompidou Group, 3rd Research platform meeting Experts
15–16 November Lisboa XV Congresso Prosalis ‘Estilos de vida e 
comportamentos aditivos – saúde, imigração, 
contexto prisional e exclusão social, numa 
perspectiva de reintegração'
Experts
23 November Lisbon Seminário ‘Homens e mulheres em Portugal’ Policy makers
28–30 November Caracas Meeting of EU and LAC Drugs Observatories Policy makers
5–6 December Baltimore Rosita 2 meeting Experts
Crime and supply
4 February Paris Pompidou Group, Expert Forum on Criminal 
Justice, meeting of the working party on open drug 
scenes
Experts
18–19 April Luxembourg EU Crime Prevention Network (EUCPN) plenary 
meeting
EUCPN national representatives meeting
Experts
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21–22 April Strasbourg 3rd meeting of the Expert Forum on Criminal 
Justice
Experts
12–13 May Sesimbra 11th ENFSI drugs working group – workshop on 
cannabis potency analysis
Experts
23–24 June Thessaloniki Reitox academy for Romania, Bulgaria and Cyprus 
– workshop on crime and supply data
Focal points 
from Bulgaria, 
Cyprus, 
Romania, 
Greece
15 June Loures CEPOL course 2005/09A on drug trafficking Law enforcement 
officers
14 July Brussels EUCPN national representatives meeting National 
representatives
17–18 October Edinburgh EUCPN national representatives meeting National 
representatives
20–21 October Strasbourg 4th meeting of the Expert Forum on Criminal 
Justice
Experts
14–16 November Lisbon Seminário Internacional sobre Tráfico de Cocaína 
por via Aérea, Prevenção e Investigação
Law enforcement 
officers
25 November Madrid CEPOL Course 2005/09B on Drug Trafficking Law enforcement 
officers
5–7 December London EUCPN best practice conference: ‘Violent street 
crime’
Experts
4 December London Meeting at Home Office on drug-related crime Experts
Health information networks
18–19 January Luxembourg 4th meeting of the Network of Competent 
Authorities
Policy makers 
24 January Luxembourg 1st Workshop of Health Portal’s start-up editorial 
board: Information/data inventory
Experts
28 February Luxembourg 2nd Workshop of Health Portal’s start-up editorial 
board: Theme structure
Experts
15 June Luxembourg 3rd Workshop of Health Portal’s start-up editorial 
board: Web design, prototype and further work
Experts
Treatment demand
25 May EMCDDA Technical working group meeting: gender data on 
Treatment Demand Indicator (TDI)
Experts
8–9  July Prague European integration and cannabis in new EU 
Member States
Experts
22–23 September EMCDDA European expert meeting on the TDI Experts
23 September EMCDDA Meeting on treatment demand with international 
organisations
Experts
12–14 December Sinaia Romanian TDI meeting Experts
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Youth and ESPAD
8 July EMCDDA ESPAD gender expert group meeting Experts
12–13 September Faeroe Islands ESPAD project meeting Experts
Drug-related deaths
23–25 November EMCDDA European expert meeting on key indicator ‘Drug-
related deaths and mortality among drug users’
NFPs
Population surveys
27–28 June EMCDDA Annual meeting of the EMCDDA expert group on 
the key indicator ‘Population surveys’
NFPs, Experts
29 June EMCDDA Drug availability in ‘Population surveys’ Experts
Infectious diseases
9–11 June Lisbon WHO technical consultation, in collaboration 
with the EMCDDA, on the development of clinical 
protocols on HIV and hepatitis co-infection
Experts
13–15 June Lisbon WHO technical consultation, in collaboration 
with the EMCDDA, on the development of clinical 
protocols on treatment and care protocols for 
injecting drug users
Experts
30  June–1 July EMCDDA Editorial meeting to discuss first draft of EMCDDA 
protocol for the key indicator ‘Drug-related 
infectious diseases’
Experts
18–19 October EMCDDA European expert meeting on the EMCDDA key 
indicator ‘Drug-related infectious diseases’
Experts
1–2 November Vienna Measuring and increasing coverage of HIV/AIDS 
prevention and care services for injecting drug 
users
Experts
23–25 November Madrid WHO technical consultation on AIDS mortality 
surveillance in Europe
Experts
14–15 December Malta Reitox academy workshop on drug-related 
infectious diseases
Experts
Problem drug use
20–21 October EMCDDA European expert meeting on the EMCDDA key 
indicator ‘Problem drug use’
NFPs, Experts
Programme P2 – Monitoring the responses – General
12–15 January Helsinki WHO European Ministerial Conference on Mental 
Health
Policy makers
14–15 March Paris Pompidou Group, Expert committee on ethics Experts
9 May Copenhagen Meeting with task force for prison and health, 
WHO
Experts
Prevention
17–18 March Bilbao European drug abuse prevention trial coordination 
meeting
Experts
20–21 April Figueres URBALDRO seminar on local prevention initiatives 
in Latin America and Europe
Policy makers, 
NGOs
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6–7 May Portugalete, 
Spain
Seminar on life skills in prevention Policy makers, 
NGOs
26 May–1 June Lausanne, Bern, 
Münster
Conferences on selective prevention Policy makers
6 June Perugia Interregional project on prevention mapping Policy makers
7–8 July Granada Lecturing, Doctorate course in Sociology PhD students
31 August–2 
September
Copenhagen Nordic narcotics conference Policy makers
10–12 November Vicenza Prevention conferences Policy makers
14 November Madeira Prevention conference NGOs
1 December Bilbao Conference on selective prevention with youth at 
risk
NGOs
Harm reduction
13–14 January Oslo National conference on harm reduction at street 
level
Practitioners
20–24 March Belfast International conference on reduction of drug-
related harm
Experts
7 April Porto Redução de risco a três dimensões (Monitoring 
harm reduction in Europe – achievements and 
challenges)
Policy makers, 
practitioners
30 June–2 July Barcelona 3 Conferencia Latina de reduccíon de daños 
(CLAT)
Policy makers
8 June Gdansk Phare twinning project Poland, conference on 
substitution treatment in Europe
Practitioners, 
policy makers
Prevention of drug-related crime
13 October London Prisons and public health: the next ten years Policy makers
European Demand Reduction Action (EDDRA)
27–28 September Sofia Drug prevention seminar for the Bulgarian national 
focal point
Experts
25–26 October Tbilisi, Georgia Drug prevention seminar for the SCAD  
programme
Experts
29–30 November Chisinau, 
Moldova
Drug prevention seminar for the BUMAD 
programme
Experts
Early warning system
3 March Hungary National EWS conference Network
7 April Cyprus National EWS conference Network
16–17 June Lisbon 5th annual meeting of the Reitox EWS network European 
network
11 October Poland National EWS conference Network
20 October Malta Reitox EWS academy (organised in partnership 
with Reitox unit)
Network
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25 November Romania National EWS meeting (organised in partnership 
with Reitox unit)
Network
Programme 4 – Monitoring national and Community strategies – General
17–20 February Paris Scientific Committee of the MILDT-INSERM Experts
7–9 March Vienna Commission on Narcotic Drugs Policy makers
29–31 March Brussels Horizontal Drugs Group Experts
5 April Luxembourg National drug coordinators meeting Policy makers
10–12 May Brussels Horizontal Drugs Group Experts
18–20 June Brussels Horizontal Drugs Group Experts
30 June Brussels Meeting on evaluation of the EU action plan with 
European Commission
Policy makers
5 July Paris Scientific Committee of the MILDT Experts
10–12 July Strasbourg 2nd Franco-German conference on Addictions Experts
13–14 July Brussels Horizontal Drugs Group Experts
8 September Brussels Horizontal Drugs Group Experts
28–29 September Brussels Horizontal Drugs Group Experts
17 October Brussels Meeting on evaluation with Commission/UNODC Policy makers
23–28 October Budapest + 
Marseille
48th ICAA conference + IEP Aix-en-Provence Scientists, 
experts
30 October–2 
November
Vienna UNODC expert group meeting on measuring 
progress in demand reduction
Experts
19–20 November London Berkeley conference Experts, policy 
makers
27 November Caracas EU-LAC drug observatories conference Experts, policy 
makers
December Paris Scientific Committee of the MILDT Experts
National drug strategies
2 May Split Assistance to Croatian national drugs strategy Policy makers
8–12 July Rome EU drugs strategy presentation Policy makers
20–23 October Budapest Informal drug policy dialogue Policy makers, 
experts
Drugs legislation
21–22 April Amsterdam Seminar ‘European criminal intelligence model’ Experts
12–14 October Strasbourg Ethics meeting – Pompidou Group Experts
Treatment and social rehabilitation
11–15 May Greece 10th European conference on rehabilitation and 
drug policy
Professionals 
NGOs
18–22 May Slovenia 2nd Adriatic drug addiction conference Policy makers, 
experts
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20–23 November London Association of chief police officers of England, 
Wales and Ireland conference
Policy makers, 
professionals
Reitox academies
1–3 June Budapest Reitox academy on ‘Relations with the media’ NFPs
27–29 June Thessaloniki Reitox academy on 'National reporting' NFPs
26–29 September EMCDDA Reitox academy on ‘Harm reduction core data’ NFPs
14–15 November Valletta Reitox national academy on ‘Drug-related 
infectious diseases indicator 
NFPs
14–16 December EMCDDA Reitox academy on ‘Prevention core data’ NFPs
Annex 4 
Members of the EMCDDA’s statutory bodies
Members of the Management Board
Chairman 
Marcel Reimen
Vice-Chairman 
Ralf Löfstedt
Country/organisation Representatives Alternates
Belgium Claude GILLARD Philippe DEMOULIN
Czech Republic Ivo KACABA Tomas BURIL
Denmark Mogens JÖRGENSEN Mie SAABYE
Germany Marion CASPERS-MERK Elfriede KOLLER
Estonia Maie ALAS Andri AHVEN
Greece Christos GIANNAKIS C. N. BALLAS
Spain Carmen MOYA GARCIA Francisco PÉREZ PÉREZ
France Didier JAYLE François POINSOT
Ireland David MOLONEY
Italy Andrea FANTOMA Stefania ROTA
Cyprus Kyriakos VERESIES Stelios SERGIDES
Latvia Astrida STIRNA
Lithuania Audroné ASTRAUSKIENÉ
Luxembourg Chairman Mike SCHWEBAG
Hungary Katalin FELVINCZI 
Malta Richard MUSCAT
Country/organisation Representatives Alternates
Netherlands Marcel DE KORT
Austria Franz PIETSCH Johanna SCHOPPER
Poland Piotr JABLONSKI Bogumila BUKOWSKA
Portugal João GOULÃO Manuel CARDOSO
Slovenia Milan KREK
Slovakia Blažej SLABÝ Lucia KISSOVA
Finland Tapani SARVANTI Kari HAAVISTO
Sweden Vice-Chairman
United Kingdom Nick LAWRENCE Gabriel DENVIR
European Commission Luis Romero REQUENA
Francisco FONSECA MORILLO
Matti RAJALA
Carel EDWARDS
European Parliament Sir Jack STEWART-CLARK
Santiago DE TORRES SANAHUJA
Carla ROSSI
Wilmya ZIMMERMANN
Norway Inger GRAN
Scientific Committee Salme AHLSTRÖM
Observers – International organisations
UNODC Nasra HASSAN
Council of Europe 
Pompidou Group
Klaus FUCHS
WHO Haik NIKOGOSIAN
Observers – Candidate countries
Bulgaria Tzveta RAICHEVA
Romania
Turkey Ismail SEVIMLI
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Members of the Scientific Committee
Country Member Institution
Finland Chair
Prof.Salme AHLSTRÖM
Research Professor
National Research and Development Centre 
for Welfare and Health - STAKES
Helsinki
France Vice-Chairman
Dr. Jean-Pol TASSIN
Research Director
INSERM at Collège de France
Unit INSERM U 114 – Neuropharmacology
Paris
Belgium Prof. Joris CASSELMAN Centre for Forensic Mental Health
Catholic University of Leuven
Prof. Brice DE RUYVER Institute for International Research on 
Criminal Policy (IRCP)
Ghent University
Denmark Dr. Anne-Marie SINDBALLE National Board of Health
Education Centre
Copenhagen
Germany Dr. Christina POETHKO-MÜLLER Federal Institute for Drugs and Medical 
Devices 
Bonn
Estonia Dr. Maarike HARRO Director General
Health Development Institute
Tallin
Greece Dr. Ioannis DIAKOGIANNIS Aristoteleio University of Thessaloniki
Spain Dr. Milagros DIEGO RISCO Government Delegation
National Plan on Drugs
Madrid
France Prof. Dr Yann BISIOU Paul Valéry University
UFR-IV AES
Montpellier
Ireland Prof. Desmond CORRIGAN Director 
School of Pharmacy, Trinity College
Dublin
Italy Prof. Carmelo FURNARI Public Health Department
“Tor Vergata” University
Roma
Latvia Prof. Girts BRIGIS Professor in Public Health and Epidemiology
Head of Dep. of Public Health and 
Epidemiology
Riga Stradins University
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Country Member Institution
Lithuania Dr. Robertas BADARAS Chairman of 
Lithuanian Society of Clinical Toxicology
Vilnius
Luxembourg Prof. Dr. Robert WENNIG National Health Laboratory
University Centre of Luxembourg
Malta Dr. Maja Miljanic 
BRINKWORTH
Ministry for the Family and Social Solidarity
Valletta
Netherlands Prof. Dr. Henk F.L. GARRETSEN Faculty of Social and Behavioural Sciences
Tilburg University
Austria Dr. Wolfgang WERDENICH Office of Justice/JA FAVORITEN
Vienna
Poland Prof. Jan Czeslaw CZABALA Institute of Psychiatry and Neurology
Warsaw
Portugal Dr. João GOULÃO
Slovakia Assoc. Prof. Alojz NOCIAR General Secretariat of the Board of Ministers 
for Drug Dependencies and Drug Control
Bratislava
Sweden Prof. Björn HIBELL Swedish Council for Information on Alcohol 
and other Drugs (CAN)
Stockholm
United Kingdom Prof. Sheila BIRD MRC Biostatistics Unit
Institute of Public Health
University Forvie Site
Cambridge
Norway Dr. Astrid SKRETTING Senior Researcher
National Institute for Alcohol and Drug 
Research
Oslo
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Annex 5  
Use of the available resources in 2005
ABM presentation of the EMCDDA 2005 budget in accordance with content and costs of 2005 work programme
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Revenues
Expenditure (Direct costs by programme commitments)
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nnexes
Expenditure (Direct costs by programme commitments) continued
2005 budget appropriations and execution by nature of 
expenditure 
Financial and accounting management 
A budget of €12.815.625 was adopted for the implementation of the 2005 work 
programme. The budgetary figures for 2005 are presented in the tables below.
Budgetary provisions and appropriations, 2005
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Execution of the budget: credit consumption, 2005 (Commitments)
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EMCDDA balance sheet at 31 December 2005
Assets
EMCDDA balance sheet at 31 December 2005
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Budget out-turn account 2005: revenue and expenditure
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